[{"article": "OMT also reduced the in-hospital mortality rates of those with the highest severity of illness.\nDisclosures: The basis for this analysis, The Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE) clinical trial, was funded by a consortium of foundations including the Foundation for Osteopathic Health Services.\nWhile antibiotic therapy is the current standard of care, the emergence of resistant bacteria is a global threat and provides an incentive to explore adjunct treatments that can improve their efficacy,\" said James Bailey, DO, assistant professor in physical medicine and rehabilitation at Rowan University School of Osteopathic Medicine.\nStudy published in the Journal of the American Osteopathic Association finds OMT plus antibiotics reduces risk of death for the most severely ill patients\n\nCHICAGO--August 29, 2016-- An analysis of multicenter randomized controlled clinical trial found osteopathic manipulative treatment (OMT) for pneumonia reduced length of hospital stay in adults 50 to 74 years old and lowered in-hospital mortality rates for patients 75 and older.\nThe study analyzed 375 patients ages 50 or older who were randomly assigned to three groups, either receiving OMT, a light touch or conventional care only.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We gave this a pass for barely meeting the criteria. The release notes that the trial was funded by a consortium of foundations including the Foundation for Osteopathic Health Services. It doesn\u2019t specifically disclose potential conflicts of interest but directs readers to the study for \u201cfull details.\u201d\nWhen we looked at the disclosures, it was clear that the researchers were aligned with or officially affiliated with osteopathic institutions and foundations.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote multiple experts. The story should have quoted experts with differing opinions on the value of the new screening recommendations in order to provide some much needed perspective. The story could have been much improved by the addition of quotes from researchers who may have concerns about the broad use of testing or by interviews with women who chose not to be tested.", "answer": 1}, {"article": "ISI Group analyst Mark Schoenebaum said although the vemurafenib results look the most encouraging, the findings are unlikely to make a difference for current sales estimates, since virtually all eligible patients will be treated with both drugs, either in sequence or in combination.\nSide effects included skin rashes and joint pain.\nAbout 18 percent of patients developed a low-grade skin cancer.\nThe five-year survival rate for the aggressive cancer is just 15 percent.\nShe and others expect vemurafenib to be approved this year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source \u2013 a panel moderator \u2013 and a stock analyst were quoted.", "answer": 1}, {"article": "Patients played the role of cab drivers who picked up passengers and delivered them to one of six requested shops in the city.\nCurrently, deep brain stimulation is used to control the tremors associated with Parkinson's, symptoms of obsessive-compulsive disorder and some other psychiatric conditions, including depression.\n\"Critically, it was the stimulation at the gateway into the hippocampus, and not the hippocampus itself, that proved effective,\" senior study author Dr. Itzhak Fried, a professor of neurosurgery at the David Geffen School of Medicine at UCLA, said in a university news release.\nThe study is published Feb. 9 in the New England Journal of Medicine.\nI think just trying to work out that there is some similarity in very simple learning [processes in the brain] is important.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes an independent source. Although it does not mention whether the researchers have any conflicts of interest, the authors reported no conflicts in the disclosure forms posted online by the New England Journal of Medicine.", "answer": 1}, {"article": "WEDNESDAY, July 13, 2011 (HealthDay News) -- For men who have prostate cancer that's considered \"intermediate risk,\" radiation plus four months of hormone therapy appears to improve survival, a new study finds.\nHe noted that the radiation treatments in use today differ from those given in 1994 when the trial began.\nOver an average of over nine years of follow-up, 62 percent of the men who had combination therapy were alive, compared with 57 percent of the men who received radiation therapy alone, the researchers found.\nYou need to give long-term androgen deprivation therapy in addition to radiation to have the best results,\" Jones said.\nThe report was published in the July 14 issue of the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from the lead author of the study reported on along with quotes from the expert in the field who wrote an editorial about the study which accompanied its publication.", "answer": 1}, {"article": "For more information, please see www.arthrokinex.com\nSignificantly better concentration, healing/pain reduction durability, faster production (just one hour), one-fifth the price, and chemical additive free, IRAPjoint\u2122 is now available in multiple physician practices throughout the United States.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\nThe European-based process was the inspiration for Dr. Barreto of Oklahoma City, Oklahoma to work on developing a stronger, more effective, and more cost-efficient version in the United States.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This news release was sent out by the clinic that developed and now markets this treatment, so the conflict of interest is fairly obvious. Another big conflict of interest should have been noted, but wasn\u2019t. The one research trial published on this therapy was conducted by a physician who has ownership in the clinic and sits on the company\u2019s board of directors. This fact, which was disclosed in the published study but not the news release, forms a clear conflict of interest.", "answer": 0}, {"article": "A sticky mucus clogs organs, particularly the lungs and liver.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\n\u201cEven thought it only affects a small percentage (of patients) the hope is there that we can finally do something about this disease.\u201d\n\nThe study, published in the New England Journal of Medicine Wednesday, looked at 84 people who got the drug.\n\u201cThis is the first time that we have a therapy that is directed at the cause of cystic fibrosis,\u201d says Dr. Michael Konstan, the chair of the Department of Pediatrics at Rainbow Babies and Children\u2019s Hospital in Cleveland and one of the authors of the study.\n\u201cThe fact is it is obviously going to make a very big difference in the lives of patients.\u201d\n\nCystic fibrosis is a genetic disease that causes problems with the balance of salt going in and out of cells.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThis story fails to include an independent source and fails to report financial disclosures. What\u2019s worse is that most readers probably believe there is an independent source quoted. While the average reader is likely to assume that the CEO of the Cystic Fibrosis Foundation is speaking independently, the actual fact is that the foundation is a major funder of the drug\u2019s development and may stand to profit from sales of the drug. Readers should have been told of the tight financial relationship between the CF Foundation and Vertex Pharmaceuticals.\nThe story should have also noted that the researcher quoted in the story works as a consultant to Vertex, and that employees of the company were involved in designing and conducting the trial as well as writing the final report. These disclosures were openly declared in the journal article and accompanying documents and should have been included in the story.", "answer": 0}, {"article": "\"Today\u2019s approval marks another step in an important shift toward treating cancers based on their tumor genetics rather than their site of origin in the body,\" said FDA Commissioner Scott Gottlieb, M.D.\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\nThe search for a cancer cure goes on, but in the meantime, there is hope for more effective treatments.\nFor example, immunotherapy drugs can now tag cancer cells so that it's easier for a patient's own immune system to identify and attack them.\nThe FDA announced Monday that it had approved Vitrakvi (larotrectinib), a treatment for both adult and pediatric cancer patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources mentioned in this story, which also doesn\u2019t state that all of the clinical trials have been sponsored by the company selling the drug.", "answer": 0}, {"article": "Politi said a serving of walnuts is about 14 halves, which adds up to 180 calories.\n\"Given walnuts are a high-energy food, a prevailing concern has been that their long-term consumption might be associated with weight gain,\" said study author Dr. Emilio Ros, director of the Lipid Clinic, Endocrinology & Nutrition Service at the Hospital Clinic of Barcelona, in a press statement.\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\nOther walnut studies presented at the conference, funded in part by the California Walnut Commission, suggested the omega-3 fatty acid-rich nut may also benefit gut bacteria and help reduce inflammation.\nAfter one year, both groups experienced minimal body weight, triglyceride, and HDL cholesterol changes, but the walnut-eaters had significant reductions in LDL cholesterol (\"bad\" cholesterol) compared to the nut-free control group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Close call on this one, but we\u2019re going with\u00a0Satisfactory, since the story\u00a0did identify that the walnut research was funded by the California Walnut Commission, and an independent nutrition expert was quoted\u2013although she didn\u2019t talk about the study. Ideally, an outside source could have provided commentary on the research, providing insight into the quality of the evidence.", "answer": 1}, {"article": "THURSDAY, Sept. 2, 2010 (HealthDay News) -- An experimental test that can diagnose tuberculosis in less than two hours, making only one doctor visit necessary before treatment starts, is being hailed as a potentially significant advance against a disease that kills nearly 2 million people annually, most of them in developing countries.\nFor the study, a research team led by Dr. Catharina C. Boehme, of the Foundation for Innovative New Diagnostics in Geneva, Switzerland, used the Xpert MTB/RIF test on 1,730 patients suspected of having drug-sensitive or multidrug-resistant pulmonary tuberculosis.\nThe test costs about $63 in Europe, but the company has agreed to provide it for less than half that in poor countries, said John Bishop, Cepheid's chief executive officer, as quoted in a story by the Associated Press.\n\"The test also indicates rapidly whether difficult-to-treat, drug-resistant forms are present,\" he said.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although we wish\u00a0it featured a comment from someone willing to look a bit more critically at the findings, the story did include an interview with an expert not affiliated with the study, thus meeting\u00a0the minimum standard for the criterion.\u00a0As far as we can tell, there were no\u00a0conflicts of interest that weren\u2019t identified.", "answer": 1}, {"article": "About 10 percent of the students had an abnormal EKG.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nThe American Heart Association suggests that athletes who are identified as at risk for heart problems as a result of a family history or physical exam be referred for further cardiovascular examination, which could include an electrocardiogram.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\n\"It's pretty much while they're in training or while they're on the field performing, because that's when the adrenalin is flowing,\" and that's when they're calling on the heart for peak performance.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story quotes Thomas Debauche, a Houston cardiologist and author of the screening study, and Douglas Zipes, a former president of the American College of Cardiology (ACC), both of whom are supportive of screening. It also mentions that ACC officials say that \u201cmost members\u201d support screening athletes. Although there is a suggestion that there is an opposing point of view, no such voice is quoted in the story. That introduces a clear imbalance. The story should have included the perspective of one of the many experts who would have disputed the wisdom of routine screening. It also could have mentioned that routine screening would result in more office visits and more revenue for cardiologists, thus creating a financial incentive for ACC members to promote the benefits of screening.\u00a0 \n", "answer": 0}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story obtains information from physicians not associated with the research who can provide a range of perspectives on what screening may or may not offer to provide balance.\u00a0 ", "answer": 1}, {"article": "For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\nIf women who say they are drinking at \u201clight\u201d levels are actually drinking at moderately or heavily, that might make the data on light drinking look more dangerous than they are.\nA glass of wine or two a week \u2014 and not more than one large glass on any occasion \u2014 may be safe during pregnancy, according to a large study just published in the Journal of Epidemiology and Community Health.\nThe study did find negative effects in children whose mothers drank moderately: this was defined as not having more than 3 to 6 British units of alcohol per week or more than 3 to 5 units on a single occasion.\nIndeed, these kindergartners were slightly less likely to have behavioral problems and performed somewhat better on cognitive tests than children whose mothers had abstained.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly was built on a lot of research, but it did not bring in any outside voices.", "answer": 0}, {"article": "The research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\nThe AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.\nFounded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 21,000 members throughout the world.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nAbout the American Urological Association: The 111th Annual Meeting of the American Urological Association takes place May 6 \u2013 10 at the San Diego Convention Center in San Diego, CA.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release fails to disclose that all of the study authors have financial ties to the drug manufacturer, Lipocine Inc., as consultants, principal investigators or employees, and that one is the company\u2019s founder.", "answer": 0}, {"article": "BOSTON (Sept. 14, 2016) -- Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time.\nThe findings, reported online today by the journal Cancer Discovery, raise the prospect that Ezh2 blockers, in combination with Gleevec and similar drugs, could eradicate the disease in some patients in relatively rapid fashion or could be an effective therapy for those who become resistant to Gleevec-like agents, the authors state.\n\"The stem cells' dependence on Ezh2 suggests they will be especially vulnerable to drugs that target the protein,\" Orkin remarks.\nThe other 90 percent retain a reservoir of leukemic stem cells - which initiate the disease - and must stay on the drugs permanently.\"\nIn laboratory experiments, the Dana-Farber/Boston Children's researchers found not only that Ezh2 is overabundant in leukemia stem cells but that it helps them survive and give rise to full-fledged CML cells.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We\u2019re told the pharmaceutical company Epizyme opened a phase 1 clinical trial at Dana-Farber/Boston Children\u2019s hospital. We\u2019re also told an NIH grant and Hyundai Hope on Wheels is funding the study. The release also notes\u00a0one of the authors on the study is an employee of Novartis Pharmaceuticals \u2014 which owns the (soon-to-expire) patent for Gleevec, also called Glivec.", "answer": 1}, {"article": "\"Although there appear to be some benefit of an overall lower death rate in both groups, the [special panel] recommended stopping the trial,\" Nabel said.\nBecause some of the patients were taking the drug Avandia, which has been the focus of concern that it might increase the risk of heart attacks, the researchers specifically examined whether that was a factor.\nThe researchers stressed that the findings would not alter current guidelines or treatment for most diabetics, many of whom can control their blood sugar without drugs.\nLetters were mailed to all participants Monday notifying them of the results so they could consult with their doctors about switching to the less intensive therapy.\nOver about four years, about half of the patients getting intensive treatment achieved blood sugar levels close to normal, and about half the patients in the standard treatment group achieved levels close to the average diabetic.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Comments from interviews with several individuals knowledgeable about the trial (i.e. cardiologist, people at the National Heart, Lung and Blood Institute) were included in this story.\u00a0 ", "answer": 1}, {"article": "\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\nWe want to help improve our patients\u2019 quality of life.\u201d\n\nThe study included 80 patients from 16 ECOG-ACRIN Cancer Research Group sites who had stage three or four HPV-positive squamous cell carcinoma of the oropharynx, and were candidates for surgery.\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee.\nThe study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release failed to mention any funding source or the presence or absence of a conflict for researchers.\nThe published study notes that the research was supported by\u00a0US Public Health Service grants,\u00a0the National Cancer Institute, National Institutes of Health, and the US Department of Health and Human Services. An author quoted in the release disclosed consulting and other financial relationships with seven pharmaceutical companies but no radiation device manufacturers.", "answer": 0}, {"article": "\u201cI had terrible pangs of sadness and despondency.\nI was missing my husband so badly.\u201d\n\nEven after seeing a therapist, which helped, she suffered from nightmares and couldn\u2019t bear to hear arias from their favorite operas.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\nAfter he died in 2002, she sold the Long Island house they\u2019d loved and shared, finding it too filled with memories, and moved to their country home in upstate New York.\n\u201cI volunteered, to get myself out and doing things, to fill the gaps,\u201d she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes several sources whose affiliations are well described, including a skeptical voice. There is no obvious conflict of interest, beyond the professional investment that some of these researchers might have in advancing the notion of \u201ccomplicated\u201d grief.", "answer": 1}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted for the article is the study itself. There are no quotes from independent expert sources.", "answer": 0}, {"article": "The test, a CAT scan of the heart that measures plaque buildup in the arteries, is popular because heart disease, the nation's No.\nThe study offers the most definitive estimate yet of the cancer risk from the radiation exposure that comes with increasingly popular CT scans, which provide pictures of the heart's arteries and quantify the risk of heart attack in people without symptoms.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nThe scans are sometimes criticized as an example of expensive new technologies being adopted before proof is established that they're better than cheaper existing methods \u2014 an issue at the heart of the health care reform debate.\nThe legislation was introduced in 2007 and passed quietly this year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes experts and advocates that represent the key perspectives in debate about CT screening for calcium deposits in coronary arteries. However, it does not include information on possible conflicts of interest.", "answer": 1}, {"article": "Ideally, the order goes the other way around: We test the idea, and then we implement.\u201d\n\nThese states have the fattest pets \u2014 and they might surprise you\n\nLong before they conquered the Internet, cats took over the world\n\nA kitten nursery saves tiny lives in a city aiming to become \u2018no kill\u2019\n\nBear breaks into house, plays the piano but not very well\nIn 2012, the Department of Veterans Affairs said it would not cover costs of service dogs for veterans with post-traumatic stress disorder, citing \u201ca lack of evidence to support a finding of mental health service dog efficacy.\u201d The department is now in the midst of a multiyear study on the topic, which could lead to government funding for these pooches.\nStill, they cautioned that \u201cthis study does not answer whether pet dogs have direct effects on children\u2019s mental health or whether other factors associated with acquisition of a pet dog benefit their mental health.\u201d\n\nIt was a classic case of conflating correlation and causation, which Herzog says is common.\nAnd that\u2019s just as important.\u201d\n\nFocusing too much on scientific support sometimes feels like a form of \u201cphysics envy,\u201d Beck added, \u201cwhere you try to quantify everything without appreciating it.\u201d\n\nBut there are good reasons for rigorous research on animals and mental health.\nThe study was designed to avoid some of the pitfalls that Crossman has seen elsewhere, which is why some of the 78 young participants got to play only with a fuzzy blanket \u2014 because tactile stimulation is known to reduce stress \u2014 and why others simply waited for the 15 minutes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a strong point of the story. It cites multiple sources, clearly identifies the affiliation of all sources, and places those affiliations in a context that readers can understand. For example, the story includes input from a source at the Human-Animal Bond Research Initiative (HABRI) \u2014 and explains that HABRI is a pet-industry backed organization that funds research on the topic of therapy animals.", "answer": 1}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviews both supporters and critics of the diabetes surgery. He also makes clear that the surgeons who advocate using bariatric surgery for diabetes have a big financial stake in the issue.\u00a0The published papers he cites all appeared in credible journals. ", "answer": 1}, {"article": "Unlike traditional stents that remain in place after implantation, Absorb is designed to disappear fully within three years of the procedure.\n\u201cNo metal may also reduce the potential of future blockages that occur with permanent metallic stents.\u201d\n\nData released in October concluded Absorb was comparable to Abbott\u2019s own Xience drug-coated metal stent in safety and effectiveness but showed a higher risk of heart attacks and blood clots.\n\u201cNo metal means the treated artery can pulse and flex naturally as demands on the heart change with everyday activities,\u201d said Gregg Stone of Columbia University Medical Center, who led clinical trials for Absorb.\nThe approach holds particular promise for patients whose coronary artery disease could require multiple implants over the course of several decades, said Mitchell Krucoff, a professor at Duke University Medical Center who has advised Abbott on Absorb.\nThe stent, called Absorb, is made of a plastic similar to dissolving sutures and offers patients an alternative to metal stents currently used to prop open arteries cleared of blockages.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both scientists quoted in this story are connected in some way to Abbott Labs; one is a (presumably paid) adviser to the company while the other led the company\u2019s clinical trial. \u00a0They are clearly identified.\u00a0 A reader would likely infer, correctly, that development of the new device has been funded by the lab. But had the reporter sought out an independent source or two, the murky nature of long-term effects of the stent might have become more obvious.", "answer": 0}, {"article": "TUESDAY, Nov. 15, 2011 (HealthDay News) -- An apple a day won't necessarily keep the doctor away, but three kiwis just might help, at least according to a small study that showed that the brown, fuzzy fruit may lower blood pressure levels.\nA blood pressure reading that is less than 120/80 is considered ideal.\nThey changed nothing in their diet other than adding the fruit.\nIn addition, the study looked at the whole fruit, not individual nutrients.\nSystolic blood pressure is the upper number in a blood pressure measurement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources were quoted.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A large waistline more than doubles the risk that people in their 40s will develop precancerous cells in the colon, according to Korean researchers.\nOne in 40 of those younger than 50 years had late-stage polyps, but no one actually had colon cancer.\nThe chances of finding abnormal cells during a screening test were just as good in younger men with too much belly fat as in slimmer men over 50.\nDuring widely used colonoscopy, for instance, bleeding or perforation of the colon may happen in rare cases.\nBy contrast, two of those over 50 did, and late-stage polyps were almost twice as common in this age group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several independent experts who provide very valuable perspectives.", "answer": 1}, {"article": "Aug. 4, 2010 -- The plant extract resveratrol, found in the skin of red grapes, appears to suppress inflammation and may fight aging in humans, according to a new study.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\nThe volunteers took pills once a day for six weeks.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nFasting blood samples were taken at the start of the trial and then at intervals of one, three, and six weeks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only two authors of the study were quoted \u2013 no independent expert source was cited. ", "answer": 0}, {"article": "Contrary to earlier reports, giving acetaminophen (Tylenol, etc.)\n\"We found no matter how you slice it, there was absolutely no difference between Tylenol and Motrin,\" says senior investigator and corresponding author Wanda Phipatanakul, MD, MS, of Boston Children's Hospital's Division of Allergy and Immunology.\nThe study was funded by The National Heart, Lung and Blood Institute's Asthma Network (AsthmaNet) and grants from the National Institutes of Health (HL098102, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, HL098103, HL098115, TR001082, TR000439, TR000448, TR000454, K23AI104780, and K24AI106822).\n\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Boston Children\u2019s Hospital discloses the fact that the National Institutes of Health and the National Heart, Lung and Blood Institute\u2019s Asthma Network (AsthmaNet) funded the study.\nHowever, no mention is made of the ties several of the researchers have to Pfizer, the maker of Children\u2019s Advil, and to McNeil Consumer Healthcare and Johnson & Johnson, makers of Tylenol.\nNot providing the potential conflicts of interest earns the release a Not Satisfactory rating here.", "answer": 0}, {"article": "Dr. Eric A. Klein, chairman of the Glickman Urological and Kidney Institute at the Cleveland Clinic, said that he would like to see the findings of the new study independently confirmed, but that other studies also have suggested that the risk of cancer is low in men whose P.S.A.\nDuring that time, there were 43 cases of advanced prostate cancer and 35 deaths in the group.\nscore of 2.0 or higher at the age of 60 was highly predictive of developing advanced prostate cancer, or dying of the disease, within the next 25 years.\nscore of 1.0 or lower at age 60 had a very low individual risk of death from prostate cancer over the next 25 years, the study found: just 0.2 percent.\nscreenings, saying it should be a choice discussed between a man and his doctor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0One clinician associated with the featured study reported on and an expert in the field without direct links with the study were quoted for this story.", "answer": 1}, {"article": "\"Getting double-blind clinical studies like this one published helps to bring credibility to parental reports.\"\n\"This is the first study that looked at whether oxytocin has an effect on social behavior, which is a major deficit in autism,\" said Angela Sirigu, who directs the National Center for Scientific Research in France and led the study, published online by the Proceedings of the National Academy of Sciences.\n\"All the data seem to suggest that manipulating the oxytocin system has a powerful effect on the core symptoms of autism,\" said Eric Hollander, director of the compulsive, impulsive and autism spectrum disorders program at the Montefiore Medical Center in New York.\n\"I think it's going to be a very exciting finding for a lot of people,\" said Alex Martin, chief of cognitive neuropsychology at the National Institute of Mental Health.\nBecause previous research has indicated that some people with autism might have abnormally low levels of oxytocin, conducting tests to identify those people and administering them the hormone might help as well, said Karen Parker, an assistant professor of psychiatry at Stanford University School of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does use several independent sources apart from the study authors. The study authors themselves declared no conflicts of interest. \nWe welcomed the balanced addition of Clara Lanjonchere\u2019s cautionary note\u00a0in the last paragraph. It provides balance to the story, offsetting the enthusiasm expressed by other sources.\u00a0", "answer": 1}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not include any independent sources.", "answer": 0}, {"article": "Chest compressions or CPR can help restore circulation, increasing the odds of survival.\n\u201cIn contrast, if CPR is not initiated before the arrival of the emergency medical services, only 1 in 30 people survive a cardiac arrest.\u201d\n\nFor the current study, researchers looked at 30-day survival for patients who had cardiac arrests outside of a hospital between 2005 and 2011.\n\u201cEarly CPR saves lives, and the lack of CPR efforts from bystanders could result in significantly decreased chances of survival,\u201d said lead study author Dr. Shahzleen Rajan of Copenhagen University Hospital in Denmark.\nThe biggest obstacle to bystander CPR remains that too few people know how to do it, said Dr. Peter Pons, an emergency physician in Denver and professor emeritus at the University of Colorado School of Medicine.\nIf the ambulance took more than 13 minutes, the survival rate was 3.7 percent in the CPR group and 1.5 percent for the others - a difference that wasn\u2019t statistically meaningful.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two independent experts whose specific credentials are clearly presented. These sources are cited on the general mechanism of CPR and the importance of starting CPR early. Ideally, they\u2019d also speak to the research itself, providing context on what the general public should know. But given that the story presents the research accurately, and included a discussion of limitations, this is a minor concern here.", "answer": 1}, {"article": "WASHINGTON (Reuters) - Viagra, developed to help ailing hearts long before it got a more high-profile job fighting erectile dysfunction, might help treat heart symptoms of muscular dystrophy, researchers reported on Monday.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nBecause of the involvement of the X chromosome, boys are far more likely to be affected than girls, who have two copies of the X chromosome and, thus, are likely to have a \u201cspare\u201d copy of the healthy gene.\nThe team, working with funds from the NIH and non-profit groups, tested Viagra in mice that had heart damage similar to that seen in muscular dystrophy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story gets credit for reporting that the study was funded by the NIH and non-profit groups. But it does not appear that anyone was interviewed for this story, neither researchers nor independent experts. The quotes are excerpts from the journal article.", "answer": 0}, {"article": "Dec. 21, 2009 -- A fatty substance found naturally in the lungs may provide a natural defense against respiratory syncytial virus (RSV) infection.\nResearchers say that until now, the function of POPG has been unclear.\nPOPGis one of several lipids found in the fluid that lines the air sacs of the lungs.\nIt is also inexpensive and easy to use.\nThere is no vaccine or easy, effective treatment for RSV.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source is interviewed in the story. ", "answer": 0}, {"article": "WEDNESDAY, May 11, 2011 (HealthDay News) -- It may be possible to assess a man's fertility by checking his \"anogenital distance,\" the gap between his scrotum and anus, a new study suggests.\nOne expert who's done her own research in this area applauded the study.\nThey measured the scrotum-anus distance as well as the penis length of 117 infertile and 56 fertile men visiting an andrology clinic.\nFurther research is needed to compare techniques for measuring anogenital distance and assess their accuracy, he and his colleagues said.\n\"First, this could represent a noninvasive way to test testicular function and reproductive potential in adult men,\" he said in a Baylor news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent experts were quoted \u2013 although one is identified as doing research in this field so her laudatory comments about the importance of this work might be understandable.", "answer": 1}, {"article": "In dark suits and blue shirts, with serious expressions on their round faces, they walked to stand next to their mother in a very beige room outside Washington, D.C.\nIn an e-mailed statement, FDA spokesperson Sandy Walsh confirmed that the FDA\u2019s decisions are all \u201cbased on an assessment of the available data and whether the benefits of the drug outweigh its risks.\u201d That data can include the experience of patients like Max, Rowan and Charlie.\nJust because a drug doesn\u2019t measure up in that way, he says, \u201cdoesn\u2019t mean the drug is not effective.\u201d\n\nBut even if the FDA agrees to overlook some of the negative data about ataluren, insurers may not.\nI didn\u2019t expect it to look like this.\u201d\n\nBut not everyone considers ataluren to be a miracle drug\u2014with good reason.\nThe drug, called Exondys 51 or eteplirsen, allows the genetic machinery that produces the protein to skip over the mutated part to make something that will work better.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quite a few sources were interviewed for the story. And, all sources are clearly identified, including the CEO of the company that is apparently funding the clinical trials.\nHowever, we do think the story would have been stronger had it tapped the viewpoints of an expert in muscular dystrophy who has no vested interested in the drug receiving approval.", "answer": 1}, {"article": "Treatment typically involves the use of inhaled steroids and bronchodilators to open airways and make breathing easier.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nCOPD is the umbrella term for chronic lung diseases, including chronic bronchitis and emphysema.\nIt is often marked by a chronic cough and shortness of breath.\nPeople who received real acupuncture also showed improvements in their quality of life and ability to exercise, according to researchers from Kyoto University and Meiji University of Integrative Medicine in Kyoto, Japan.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story does not directly quote the study\u2019s authors, it does include three independent experts \u2013 two medical doctors and one licensed acupuncturist. However, the article could have benefited if an independent expert specifically addressed any limitations of the study or of acupuncture.", "answer": 1}, {"article": "For most patients the cravings really do disappear.\nAsked how many people gain the weight back, Dr. Hutcher tells Stahl, \"You know I think when you're dealing with an incurable disease that kills many people, if you have an 85 to 90 percent success rate, that's pretty darn good.\"\nHere's how Hutcher does the surgery: first, he sections off a small pouch of the upper part of the stomach, which is then attached to a lower part of the small intestine, bypassing most of the stomach, so that there's not a lot of room for food.\n\"If you listen to your patients, they come back and they say, 'Doctor, you put the fire out,'\" Hutcher says.\nBut here's something the medical world is just realizing: that the gastric bypass operation has other even more dramatic effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The segment draws on the experience of eight patients, all of whom have had positive results. \nIt also quotes at length a surgeon who is an enthusiastic advocate of the surgery, a surgeon participating in Brazilian clinical trials on the procedure\u2019s effect on diabetes and a physician who had the surgery himself with positive results.\nA doctor who expresses mild skepticism about the total weight that follows surgery is quoted. \u00a0\nThe segment quotes an American Cancer Society epidemiologist, who describes the links between obesity and several cancers.\nAbsent are skeptics who could raise questions about such issues as the long-term effectiveness of the surgery\u2019s ability to \"cure\" diabetes, the nutritional challenges of a post-surgical diet, and the wider range of outcomes observed for different forms of the surgery.\u00a0\nAbsent also are patients who had outcomes different from those repeated so frequently here: Those who developed illness due to nutritional deficiences, those who regained the lost weight, and those whose diabetes was not \"instantly cured.\"\u00a0 \u00a0", "answer": 0}, {"article": "At the start, about 12% said they didn\u2019t exercise, and the rest said they exercised anywhere from \u201cup to 30 minutes\u201d to \u201cmore than 4 hours\u201d a week.\nFor people who worked out more, no additional benefits were observed.\nOver the next decade, about 7% of people in the study developed depression, and about 9% developed anxiety.\nThat exercise doesn\u2019t have to be intense, either, they say.\nNo relationship was observed between exercise and later anxiety, but the researchers did find a link between exercise and later depression.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t include any content from independent sources.", "answer": 0}, {"article": "Related: Is Your Medication Helping or Hurting?\n\"It gave us an answer \u2014 that this was her physiology and her genetics and not something in her head.\u201d\n\nThe Avera Institute for Human Genetics (AIHG) in Sioux Falls, South Dakota is among several institutions exploring the role of pharmacogenomics \u2014 the science of how our inheritance and genetic makeup influences the way we metabolize medications.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nAccording to a study conducted by the Mayo Clinic that looked at one genetic test similar to many used in hospitals \u2014 GeneSight Psychotropic \u2014 symptoms of depression were reduced by 70 percent compared to treatments prescribed without genetic testing.\nShe was also prescribed selective serotonin reuptake inhibitors (SSRIs) \u2014 a class of drugs including Prozac which are used to treat anxiety and depression \u2014 but they \"made me feel like I was losing my mind,\" Ellis told NBC News.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only three sources in the story are two employees of different branches of the Avera medical organization, which developed the specific genetic test (Genefolio) discussed in the article, and a depression patient whose doctors used that test to help identify why the patient was responding so poorly to previously described drugs.", "answer": 0}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "TUESDAY, Jan. 17, 2012 (HealthDay News) -- Combining two drugs that target an aggressive type of breast cancer known as HER2-positive appears to work better than using either drug alone, researchers report.\nAt that point, researchers evaluated who had better responses.\nAll had HER2-positive breast cancers.\n\"What we observed was a massive improvement in response,\" Baselga said.\nThose given Tykerb alone had a 25 percent response.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source quoted.\u00a0 Drug company funding of the study was noted.\n\u00a0", "answer": 1}, {"article": "\"The work by [first author] Price et al.\n\"In this study, by using an elegant adult-inducible SIRT1 knock-out mouse model, the authors now provide compelling evidence that SIRT1 is required in vivo [in the animal] for the effect of resveratrol on AMPK activation and on mitochondrial function,\" Marambaud said.\nTUESDAY, May 1, 2012 (HealthDay News) -- Researchers have found new evidence showing that resveratrol, a compound found in red wine, may play a role in preventing cell aging.\nIn 2010, according to news reports, the company, which is owned by GlaxoSmithKline, halted clinical trials of resveratrol, but Sinclair said the company continues to develop improved synthetic molecules.\nWhile previous studies have also suggested that resveratrol may have anti-aging properties, the precise mechanism of resveratrol has been controversial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Yes, the story turned to an independent expert at the end.\nAnd, yes, it noted the conflicts of interest for the senior study author.\nBut it seemed to go out of its way to include a quote from the CEO of the drug company developing reseveratrol-like molecules \u2013 quoting him from an email he sent the journal that published the work.\u00a0 And it never explained WHY the company halted clinical trials of resveratrol in 2010.\u00a0 Before letting the CEO make new claims (\u201cfirst definitive evidence\u201d) about a new approach, it might have been helpful to review for readers why another approach was abandoned.\nWe think that\u2019s only half a loaf, and give it an unsatisfactory score for that reason.", "answer": 0}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no additional sources of information and no attempts an independent corroboration.\u00a0 The story does not mention that AstraZeneca, makers of anastrozole, funded the research and the lead authors of the study receive speaking fees and other honoraria from AstraZeneca.", "answer": 0}, {"article": "Five immune system autoantibodies have been linked to type 1 diabetes.\nThe current study was randomized and double-blind (meaning neither the parents nor the researchers knew who was getting what), and compared regular baby formula to one that was made easier for babies to digest because the proteins were broken down (extensively hydrolyzed).\n\"The data in this study is not sufficiently strong to support recommending any changes for parents,\" said the author of an accompanying editorial, Dr. David Harlan, co-director of the Diabetes Center of Excellence at the University of Massachusetts Memorial Medical Center in Worcester.\nWhen Finnish researchers randomly assigned 230 babies at high risk of type 1 diabetes to receive either a regular infant formula, or one that was extensively hydrolyzed -- which means the proteins in the formula are already partially broken down and more readily available for digestion -- they found that the extensively hydrolyzed formula cut the rate of developing diabetes-linked antibodies in the blood by about half.\nAccording to Knip, the take-home message from the study is that \"it is possible to reduce considerably the initiation of the diabetes disease process in at-risk children in a simple and safe way: weaning to an extensively hydrolyzed formula.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several clinical experts who provide explanation of the results and put these into context with current formula recommendations.\u00a0 Study authors are cited as well as clinical experts who feel the research is noteworthy, but should not change recommendations for a hydrolyzed formula to prevent Type 1 diabetes.\u00a0\u00a0 Affliations of all sources are listed in the story postscript.", "answer": 1}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites two researchers, each of which discusses the field at large as well as their own work. That\u2019s enough to earn a satisfactory rating here, though it would have been valuable to garner input from a mental health expert, given that the two people quoted \u2014 while actively involved in the field \u2014 specialize in issues related to emergency medicine (internal medicine) and computer science. There do not appear to be conflicts of interest, though the story doesn\u2019t explicitly state that (or where the funding came from). A look at the relevant paper shows that funding came from the Robert Wood Johnson Foundation and the John Templeton Foundation.", "answer": 1}, {"article": "For the trial, Caroline Robert of Gustave Roussy and Paris-Sud University in France and colleagues treated 655 patients with advanced melanoma.\nVirtually all of them are still in remission.\nThere are side-effects, including fatigue, itchiness and rash.\nRates are rising, in part because tanning became fashionable.\nAnd 61 of the patients, or 9 percent, have stopped taking the drug after their tumors went away.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "At least two outside sources were quoted in addition to a study spokesperson.", "answer": 1}, {"article": "Allowing more basic emergency medical service (EMS) staff to administer naloxone could reduce drug overdose deaths that involve opioids, according to a Centers for Disease Control and Prevention (CDC) study, \u201cDisparity in Naloxone Administration by Emergency Medical Service Providers and the Burden of Drug Overdose in Rural Communities,\u201d published in the American Journal of Public Health.\nThis website is archived for historical purposes and is no longer being maintained or updated.\nThe findings indicate naloxone was most likely to be administered to women, people between the ages of 20 and 29, and people living in suburban areas.\nThe use of naloxone by rural EMS staff, however, was only 22.5 percent higher when compared with urban EMS naloxone use.\nIn 2013, more than 16,000 deaths in the United States involved prescription opioids, and more than 8,000 others were related to heroin.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear that the release comes from the CDC, and the release links back to the CDC website, which makes it clear for anyone who might not know that the CDC is funded by the federal government (your tax dollars).", "answer": 1}, {"article": "If studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nThe study appears online in the Journal of Clinical Investigation.\nAdults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\nResearchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent clinician, who offers useful context. We are not aware of any conflicts that should have been identified.", "answer": 1}, {"article": "Scientists in Britain say they have developed a blood and urine test that can detect autism in children.\n\u2022 Note added 27 February 2018: The UK autism research charity, Autistica, provided the following comment to the Guardian: \u201cThis is a small, early-stage study which may explain one biological difference in autism.\nGenetic causes are thought to be responsible for about a third of cases of ASD, while the rest are believed to be caused by a combination of environmental factors, mutations, and rare genetic variants.\nThey found the most reliable of the tests they developed was examining protein in blood plasma, which found children with ASD had higher levels of the oxidation marker dityrosine (DT) and certain sugar-modified compounds called advanced glycation end-products (AGEs).\nThis may help us improve the diagnosis of ASD and point the way to new causes of ASD.\u201d\n\nThe research has been published in the journal Molecular Autism.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources. Including independent experts could have given the story much-needed context, including whether there are other studies looking for potential biomarkers for ASD.\nConflicts of interest are not mentioned, and we could find none.", "answer": 0}, {"article": "WASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\nRisk-based screening is a poor approach.\n\"All women age 40 and over can benefit from annual mammography.\nThe SBI includes leading international breast imaging specialists nationwide among its membership.\nBreast cancer remains the second leading cause of deaths among women in the United States.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The Society of Breast Imaging and the American College of Radiology are clearly indicated.", "answer": 1}, {"article": "We know early intervention is extremely important.\nThe technology has been around for awhile -- developed in the late 1920s, it has been used for more than 60 years to detect seizures in epileptics.\nTUESDAY, Feb. 22, 2011 (HealthDay News) -- By analyzing patterns in the brain's electrical activity, researchers say they've been able to assess autism risk in children as young as 6 months of age.\n\"In this study, we have taken the first step in showing that there is definitive information in the electrical signals measured by EEG to distinguish normal controls from infants at high risk for developing autism,\" Bosl said.\n\"My hope is we would have a simple way of measuring brain activity in every child and see the patterns emerging that might track autism characteristics,\" Bosl said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story spent the most time quoting the lead author,\u00a0William Bosl from Children\u2019s Hospital Boston. It also quoted Dr. Joshua Ewen, a neurologist and director of the clinical neurophysiology laboratory at the Kennedy Krieger Institute in Baltimore. We wish the story had made better use of Ewen and allowed him to help readers make sense of the study. His comments come too late to dampen the boosterism of Bosl hoping for every child to be hooked up to an EEG at nine months of age. Nonetheless, in citing an independent source, the story barely meets the criterion.", "answer": 1}, {"article": "[Seriously, why does anyone under 18 still have access to a tanning bed?]\nThe FDA warned, however, that the treatment also has the potential to kill other types of cells, such as skin cells, if injected improperly.\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\nKeith Leonard, chief executive of Kythera, the California-based firm that developed Kybella, said at a conference last month that he believes the new treatment \"can drive a very large market and leave very satisfied patients.\"\nA Kythera representative said Wednesday that the new treatment likely won't be available until June, as it must train doctors to administer Kybella, and that the company would not have more details about the potential cost of the drug until after its launch.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relied almost entirely on a news release and prior comments from representatives of Kythera. It quotes a company official saying the drug\u00a0\u201ccan drive a very large market and leave very satisfied patients.\u201d That seems imbalanced when no independent source is tapped to evaluate the claims.", "answer": 0}, {"article": "The finding is important because the latest guidelines on mammograms advise that most women can wait until the age of 45 or 50 to start having annual screenings.\nThe new study involved more than 900 women.\nNone had been diagnosed with breast cancer.\n\u2022 Women with a 20 percent or greater lifetime risk of breast cancer also should undergo screening MRIs.\nThat includes 39 percent who met the ACS criteria for above-average risk for breast cancer, and an additional 11 percent who met the American Society of Breast Surgeons' criteria.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only a study authors appear to have been interviewed for the story.", "answer": 0}, {"article": "These types of diets were then categorised as either anti-inflammatory or pro-inflammatory based on foods that affect inflammation.\n\"If we can confirm these results, then it's good news for people with Bipolar Disorder, as there is a great need for better treatments for the depressive phase of Bipolar Disorder\" said lead researcher Melanie Ashton of Deakin University in Australia.\nA total of 133 participants were randomly assigned to take a combination of nutraceuticals (compounds derived from foods such as vitamins or minerals that treat or prevent a disease or disorder) including the anti-inflammatory amino acid n-acetylcysteine (NAC), or NAC alone, or a placebo (a dummy pill) for 16 weeks.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\nWhile current medications are useful, they are better at targeting mania symptoms (the 'up' phase), leaving a lack of effective treatment for people experiencing depressive episodes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Study funders are noted on the sidebar of the hosting service, EurekAlert! It would be helpful to include that information in the body of the news release as well.\nCareful review of the author disclosures included in the study reveal no significant conflicts of interest.", "answer": 1}, {"article": "\"In conclusion, gemcitabine did not result in improved overall survival compared with fluorouracil plus folinic acid in patients with [surgically removed] pancreatic cancer,\" the authors concluded in their report.\nAt the one- and two-year markers, survival rates for that group was approximately 78.5 and 48 percent, respectively.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\nBetween 2000 and 2007, the participants were divided into one of two six-month chemotherapy groups: one receiving fluorouracil and folinic acid post-surgery and the other receiving gemcitabine.\nAt the three-year mark, patients on the gemcitabine regimen achieved an average survival rate of 23.6 months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source provides important big picture points about pancreatic cancer. More sources might have provided more context and filled in some of the holes.\nThe associations of the lead author and independent source were provided. The study authors themselves did not disclose any financial relationships.", "answer": 1}, {"article": "While they were eating the avocado-a-day diet, the volunteers saw their LDL go down by more than 13 points compared to their usual levels, Kris-Etherton\u2019s team reported in the Journal of the American Heart Association.\nThe Hass Avocado Board helped pay for the research, which was also funded by the U.S. government.\n\u201cIn the past, we used to substitute carbohydrate for saturated fat, and that would result in a low-fat diet,\u201d said Penny Kris-Etherton, chair of the American Heart Association\u2019s Nutrition Committee and distinguished professor of nutrition at Pennsylvania State University.\nSaturated fat \u2013 the kind found in meat and butter \u2013 has a different chemical structure from the unsaturated fats found in plant products.\nRepeated studies have shown it raises the risk of heart disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any independent sources. But it somewhat makes up for this omission through an extensive interview with one of the study researchers, who provides excellent context. The story also clearly states that the study received funding from an avocado industry organization.", "answer": 0}, {"article": "Of the 100,000-plus Americans waiting for a donor kidney, about one-third are \"sensitized,\" said Dr. Robert Montgomery, director of the Transplant Institute at NYU Langone in New York City.\nLast year, a landmark study proved that patients who receive transplants after desensitization live significantly longer than those who stay on dialysis.\nNow the new research suggests a simple approach -- an infusion of a particular enzyme hours before the transplant -- could offer a better alternative.\nIn the study, 10 patients had an episode of antibody-mediated rejection anywhere from two weeks to five months after their transplant.\n\"The desensitization protocols now in use are time-consuming, and they don't always work,\" she said, noting that they can leave dangerous antibodies behind.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article duly discloses that the study was conducted or somehow supported by Hansa Medical, the maker of the enzyme infusion, and quotes at least two experts not involved in the study itself.", "answer": 1}, {"article": "If you'd like to find out more about this procedure, please click here\n\"Our cardiologist said it's very unusual to see a mother and a daughter have the exact same problem,\" Marylin Hansen says.\n\"And when we find that spot, we grab the valve with the clip \u2026 and this yellow regurgitation goes away and the valve remains behind,\" Dr. Gray explains.\n\"What a miracle that she found it on the Internet, that she doesn't have to go through what I went through,\" Marylin says.\nDesperate for an alternative, she surfed the Internet and found an investigational new procedure, one that uses a tiny clip to repair the valve \u2014 and most important, does not require open-heart surgery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The interviewees were all fans and users of the procedure.\u00a0 The range of sources wasn't diverse.\u00a0 \nIt would have been beneficial to have someone comment on the difference between the procedures, the types of conditions that may be most amenable to treatment with the experimental medical device, and some more about patients for whom it might be appropriate to consider use of the device.", "answer": 0}, {"article": "\"But the [overall] rate of invasive breast cancer diagnosis was no different with or without CAD,\" Fenton said.\n\"The good news is the use of CAD was related to finding invasive cancers at smaller sizes and earlier stages than before the CAD era,\" said Kopans, also a member of the American College of Radiology's Breast Imaging Commission.\n\"There should be no argument that finding invasive cancers at a smaller size and earlier stage is beneficial,\" he said, as they are more likely to be cured.\nWhile he calls finding more DCIS with computer-aided detection also ''likely a good thing,\" he acknowledged the debate about the possibility that a very early cancer in an elderly woman may not cause a problem in her lifetime.\nAlthough the treatment of DCIS is debated among experts, Kopans said, \"In my mind, it is always worth it to find additional cancers.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments by Dr. Daniel Kopans, who was not connected with the study. \u00a0Because Dr. Kopans\u2019 comments are extensive & mainly support the use of CAD, observations by a second independent source with a different opinion would have provided needed balance for the reader. \u00a0Comments by lead study author Dr. Fenton, point out some problems with CAD but analysis by another independent source would be helpful for readers.\nKopans clearly offers a counterpoint to Fenton, but some of Kopans\u2019 statements, such as the following, should not have gone unchallenged and it would have been easy to find other experts who believe this is not the case:\n\u201cWhile he calls finding more DCIS with computer-aided detection also \u201dlikely a good thing,\u201d he acknowledged the debate about the possibility that a very early cancer in an elderly woman may not cause a problem in her lifetime. Although the treatment of DCIS is debated among experts, Kopans said, \u201cIn my mind, it is always worth it to find additional cancers.\u201d", "answer": 0}, {"article": "Ingber says some scientists are interested in using the chips to conduct research that would be unethical if performed on people, such as studying the effects of gamma radiation on the human body.\nThe sophisticated architecture of these organs-on-chips\u2014which are about the size of a thumb drive\u2014has also earned the Wyss Institute recognition in the art world with a Design of the Year award from the Design Museum and placement in the Museum of Modern Art\u2019s permanent collection.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\n\u201cThe real power of this approach is that you have a window to the inner workings of life,\u201d says Don Ingber, founding director of the Wyss Institute and a professor of Vascular Biology and of Bioengineering at Harvard University.\nIt takes up to 15 years and $5 billion for a new drug to make it through testing and earn approval from the U.S. Food and Drug Administration (FDA).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a two-source story, but both quoted researchers are leading organ-on-chip projects and so have a clear stake in this technology. One researcher created the organ-on-chip and is part of a team seeking to commercialize the technology. The other, though based at NIH, would seem to have a strong professional interest in seeing the technology succeed. The report needed an independent source, who could talk more thoroughly about the limitations of this technology and whether the expectations put forth by the article are realistic. For example, the story could have asked the head of research for a major drug company about their views on such new technologies, and whether they had any immediate plans to replace existing systems with this new one.", "answer": 0}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In the original AP version (939 words long), the reporter quoted 5 expert sources.\u00a0 In the vastly cut-down Cincinnati version (369 words), only two sources appeared.\u00a0 \nIt does not appear that anyone independent of the study in question was interviewed. \u00a0\u00a0", "answer": 0}, {"article": "The study received no funding from private industry.\nAnd, he said, the hope was that lidocaine would essentially short-circuit that bundle's headache-causing pathway.\n\"Of course, it remains to be seen if the demonstrated benefit already seen holds up over a longer period of time, and with a bigger group of patients.\"\nThe day after the procedure, average migraine pain levels had dropped from about 8 to just over 4.\nThe participants all underwent a session of \"image-guided therapy,\" in which a spaghetti-sized catheter was inserted through a nostril and into the nasal passage to deliver a dose of lidocaine to a nerve center known as the sphenopalatine ganglion.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article provided an independent source not connected to the research. Dr. Richard Lipton, director of the Montefiore Headache Center in New York City, was quoted saying the findings were \u201cpromising\u201d and \u201cvery dramatic.\u201d He does mention that the results need to be replicated in a larger, longer study. This would have been a good opportunity for the story to address some of the drug\u2019s harms, the lack of a control group in the study, as well as other migraine treatments.", "answer": 1}, {"article": "\u201cFollowing a 'healthy diet' emerges as an important strategy for prevention of neurological disease, but remains to be proved.\u201d\n\nCathy A. Sila, MD, the George M. Humphrey II Professor of Neurology and the director of the Stroke & Cerebrovascular Center at the Neurological Institute Case Medical Center of Case Western Reserve University School of Medicine in Cleveland, Ohio, says the benefits of diet and lifestyle choices in disease prevention are more important than ever, given the rising costs of health care.\n\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cNow, we see it may reduce stroke risk in people older than 65.\"\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Great sourcing \u2013 with 3 independent voices besides the study authors.", "answer": 1}, {"article": "New drug may help MS\nCurrently, the main treatment is to suppress the immune system, an approach that can leave patients vulnerable to infections and cancer.\nIt doesn\u2019t break down and contains a compound, styrene, that may cause cancer.\nIt\u2019s also clear the approach would not repair any damage already done by the disease, so the best candidates would be patients having their very first symptoms.\nThey may form their own company to develop it as a medical treatment, something that would be years away.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the story, and all the sources provide an overly optimistic view of the future for this research.", "answer": 0}, {"article": "I was glad it was done a week before and not the same day as the lumpectomy surgery.\nBecause this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\n\u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d Madrigrano said.\nWire localization requires a high degree of coordination between radiology and surgical scheduling, which can lead to delays between placement of the wire and surgery, often requiring a woman to wait long periods of time with the wire in her breast.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Since there\u2019s no study involved we rate the first half of this criterion (Funding Sources) Not Applicable. But the news release is silent on potential conflicts of interest either institutionally or with individuals mentioned. Is Dr. Madrigrano, who speaks favorably about the device, a paid consultant to the company that makes it? We would have liked some information on any institutional or individual potential (or lack thereof) for conflict of interest.", "answer": 0}, {"article": "The marketing materials suggested it already had.\nEarly data from Rafferty\u2019s trial showed that the same group of women who did benefit from 2-D digital benefited even more dramatically from 3-D. (It\u2019s worth noting that this is not a small group of people.\nDaniel Kopans, a world leader in breast imaging (he wrote the textbook of that name) and a radiologist at MGH, now says that the panel didn\u2019t \u201cunderstand mammography screening.\u201d Furthermore, he adds, the new guidelines had \u201cno biological or scientific reason\u201d behind them.\n\u201cYou know, this technology has only been approved for two months.\u201d\n\nBy the time such data do come out, mammography will surely have changed again.\n\u201cIt\u2019s a step, but it\u2019s a step by a person who has a stride of 7 feet.\u201d \u201cIt\u201d is a 3-D mammography machine, the Selenia Dimensions system, one of which sits in the breast imaging clinic at Massachusetts General Hospital that Rafferty, a radiologist, runs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were quoted in this article.\u00a0 Most of the quotes are from Dr. Rafferty, who helped to develop the 3-D equipment, and from Andy Smith, a vice-president of Hologic, the manufacturer of the equipment being profiled.\nWhile Dr. Otis Brawley of the American Cancer Society and Dr. Daniel Kopans, a radiologist at MGH, are both quoted, their quotes do not refer to 3-D imaging.\nBecause of the tendency of patients to assume that new imaging equipment is better than exisiting equipment\u00a0and that the ability to image in 3-D must be better than 2-D imaging, it is important\u00a0that an article written for the general public be balanced and based on scientific evidence.\u00a0 While certain phrases in this article appear to be an attempt at balance, there is no true balance that independent observers would provide.\u00a0 There is no scientific evidence to support the favorable quotes and positive tone of this piece.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\nThe findings bordered on statistical significance, suggesting that future clinical trials with a greater number of patients are needed to show similar benefits.\nThis preliminary study showed that three months after stroke, 182 out of every 1,000 patients treated before arriving at hospital were less disabled, including 58 patients who had zero disability, compared to people who received treatment after reaching the hospital.\nThe ambulance arrives, does the CT on-site, gives the clot-busting drug if indicated and then transports the patient to the hospital.\nEvery second counts, in the current standard of care, patients who experience stroke-like symptoms and call 9-1-1 arriving to the hospital by ambulance are assessed by clinical examination and imaging (CT or MRI scan) in the Emergency Department.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release explains the funding source and points to the abstract, which notes that one of the authors received a modest grant from a pharmaceutical company for a clinical trial for a clot-busting drug.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies solely on sources associated with GlaxoSmithKline. The lead author of the study is cited, however, the study was sponsored by this drug manufacturer. Additional oncology researchers are needed for perspective on the results of lapatinib in metastatic breast cancer patients. ", "answer": 0}, {"article": "And Medicare has established a registry to see how well large-scale screening works.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nAmong the 65- to 74-year-olds getting CT scans in the national trial, moreover, many had other serious health problems \u2014 heart disease, diabetes, hypertension, pulmonary disease \u2014 which probably contributed to only 55 percent surviving five years, compared with 64 percent among those under age 65.\n\u201cThe only way to prevent lung cancer or reduce your risk,\u201d Dr. Gould said, \u201cis to stop smoking.\u201d\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources in this story are clearly identified, but no effort is made to articulate the presence\u2014or absence\u2014of conflicts of interest. However, a quick search of these individuals does not reveal any major conflicts, so we\u2019ll rule this Satisfactory.", "answer": 1}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story utilized product claims from advertisements and comments from an individual with relevant expertise in the field.", "answer": 1}, {"article": "Plenary sessions feature the latest research on the use of and testing for cannabis, combating premature death due to preventable causes such as tobacco and alcohol, the development of an \"intelligent\" surgical knife, programmable bio-nano-chips, and the epigenetic causes of disease.\n\"This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer's disease,\" said Emma C. Harte, PhD, a research scientist at Randox Laboratories.\n\"Cerebrospinal Fluid Angiotensin-Converting Enzyme Activity Levels of Patients With Alzheimer's and Parkinson's Disease\" (A-118)\n\u2022 Researchers have shown that a specific protein in blood plasma could serve as a biomarker for early detection of AD.\n\"Plasma neuron derived exosomal protein biomarkers in the diagnosis of Alzheimer's Disease\" (A-135)\n\u2022 A new meta-analysis of studies over 12 year suggests that a possible relationship between thyroid function and an increased risk of dementia.\nThis test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with increased risk of developing Alzheimer's disease.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t say who funded the research or whether there were any financial arrangements, only that \u201cResearchers from Randox Laboratories collaborated with research colleagues at the Medical University of Vienna.\u201d", "answer": 0}, {"article": "Then last year, in a sharp turnaround, the CDC recommended that it not be used during the 2016-17 flu season after a study found it had not been very effective in the previous year, particularly among kids.\nSome of these technologies are already available on the market, while others are still being tested.\nThe company says its flu vaccine \"starter kit,\" which can vaccinate 500 people, costs $900.\nAs described by the CDC, these devices use a high-pressure, narrow stream of fluid to penetrate the skin.\nThe devices were used to quickly vaccinate large numbers of people, including members of the armed forces.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article mentions funders for all of the efforts described. But there is no independent source\u2013everyone in the story\u00a0seems to be connected to a commercial product.", "answer": 0}, {"article": "In those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\nThe findings run counter to the results of several randomized clinical trials conducted before the Food and Drug Administration gave the thumbs-up to these nicotine replacement products in the 1990s.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\nSmokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story quoted no independent experts. The only comments it used that were not from the lead researcher were from GlaxoSmithKline. \u201cBut GlaxoSmithKline Consumer Healthcare, which makes Nicorette, Nicoderm, Commit lozenges and other smoking cessation products, said that would be premature. The company noted that most of the adults in the study who used nicotine replacement products didn\u2019t use them for the recommended eight weeks. Had those people followed directions, they might have had more success.\u201d This idea appears to have been refuted in the study itself, which showed that the duration that people took the products did not seem to make a difference. A better criticism might have been that it is difficult to tell how these people truly complied with the product because they were not being actively monitored in a clinical trial but were only responding to survey questions.", "answer": 0}, {"article": "CBS News correspondent Kelly Wallace reports Kate Miller's 15-year-old son Cody killed himself just 17 days after starting the drug.\n\"We have no indication that anything about the mechanism of Singulair is consistent with these events,\" said George Philip, director of research and product development.\n\"It was the end of our world and we didn't know why, because this child was a perfectly normal healthy child, Never had a problem,\" Miller says.\nThe policy change came after the FDA was criticized for acting too slowly on information about the risks of Merck's painkiller Vioxx and, GlaxoSmithKline PLC's diabetes pill Avandia.\nFirst approved in 1998, it is part of a class of asthma and allergy drugs that includes AstraZeneca's Accolate and Critical Therapeutics's Zyflo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The segment draws on data from pre-approval and post-marketing trials, an interview with the family of a teenager who committed suicide after taking Singulair, and an interview with a clinical specialist in asthma and allergies.\nIt also reports its own observation that information about the side effects is buried on the drugmaker\u2019s website.\n\u00a0\n \u00a0", "answer": 1}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The one expert source quoted is chief scientific offer at the Alzheimer\u2019s Association, which ran the study. Readers would have benefitted from hearing a perspective from an expert or researcher who was not involved with the study.", "answer": 0}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story brings in some strong independent voices who help make sense of this complicated study: James Fang, a cardiologist at University Hospitals Case Medical Center in Cleveland, who wrote an editorial accompanying the study, Raymond Gibbons, a cardiologist at the Mayo Clinic, and Clyde Yancy, chief of cardiology at Northwestern University\u2019s Feinberg School of Medicine. Rarely do you see a story that spends as much time with independent experts as it does with the authors of the study.", "answer": 1}, {"article": "We are very interested in clarifying the best ways to prevent these infections, reducing the burden on the patients, on their infants and on the health-care system as a whole.\u201d\n\nAn estimated 1.3 million women in the U.S. delivered their babies by C-section in 2013, with surgical-site infections complicating 5 to 12 percent of those deliveries.\nThere are few circumstances when a single study should change our practice.\nThe average cost of treating those cesarean-related infections in the hospital is $3,500 and may be much higher for severe infections.\nAlthough the new study was conducted at only one hospital, the researchers said the patient population was racially diverse and that more than 60 percent received public insurance.\nA new study from Washington University School of Medicine in St. Louis offers strong guidance on the best way to reduce the infection risk.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states the funding sources. There were no apparent conflicts.", "answer": 1}, {"article": "That aching back is hard to fix, but here are a few things to try\n\nThese real-life cyborgs hack their bodies with chips, magnets and other tech\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nIn an article on Popular Science\u2019s website, Jay writes about her experience with pain and the next-generation way she\u2019s finding relief.\nAccording to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nShe also describes her path to spinal stimulation, how the device works with the body to short-circuit pain, and the many roadblocks to relief that patients face.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources quoted in the story, which was a weakness.\nIn the Popular Science column, Jay said she has a \u201cnew part-time job advocating for people in chronic pain,\u201d but not disclose who is paying her. The Washington Post story did not mention that potential conflict of interest.", "answer": 0}, {"article": "However future studies will include girls too.\nZachary Warren, who is the director of the Vanderbilt Kennedy Center Treatment and Research Institute for Autism Spectrum Disorders (TRIAD), says since there are many types of autism, \"it becomes very challenging to capture all these differences with one test.\"\nThe study included only males between the ages of 7 and 28 because they were part of a bigger research project at the University of Utah, which is following males with autism for a longer period.\n\"No one has measured what we measured,\" says Lange of the MRI test he and Dr. Janet Lainhart from the University of Utah developed.\n(The advocacy group Autism Speaks has posted videos to help parents see the signs of autism)\n\nThe earlier a child has been identified as having autism, the earlier behavioral therapies can be applied to lessen the impact of the disorder later in life.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did a far better job than the Reuters story in making use of independent sources. Both Carissa\u00a0Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine,\u00a0Zachary Warren, who is the director of the Vanderbilt Kennedy Center Treatment and Research Institute for Autism Spectrum Disorders (TRIAD), offered cautious views of the study.  ", "answer": 1}, {"article": "A new review of more than 80 studies on the two breast cancer screening methods shows breast needle biopsy was able to distinguish between cancerous and noncancerous breast lesions with about the same accuracy as surgical biopsy and less than half the risk of complications.\n\"Based on currently available evidence, it appears reasonable to substitute core needle biopsy procedures for open surgical biopsy given the comparable sensitivity and lower complication rates,\" write researcher Wendy Bruening, PhD, of the ECRI Institute Evidence-Based Practices Center in Plymouth Meeting, Pa., and colleagues.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\nIn most cases, the lump or lesion is benign or noncancerous and does not require further treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has only one source who is a lead author of the study on which the story is based.\u00a0\u00a0 It is not made explicit in the story that she is involved in the study. \u00a0The story should include additional independent clinical sources to put the new information in perspective.\u00a0 An interview with an independent expert could help\u00a0provide \u00a0information on availability of\u00a0 various methods of CNB\u00a0and their real world accuracy (e.g. are most surgeons adequately trained to perform core needle biopsies?).", "answer": 0}, {"article": "Previous studies have found women's monthly hormone fluctuations can affect everything from food cravings and digestive problems to joint pain and a whole host of other health issues.\n\"This result emphasizes the need for gender-specific programs to quit smoking, as well as taking into consideration a menstrual cycle phase during addiction treatment in women,\" the researchers conclude.\nThe study, which was published in Psychiatry Journal, involved 19 women and 15 men who were all chronic smokers but otherwise healthy.\nThe brain scans showed that during the follicular stage, cigarette imagery activated five areas of the brain which the researchers say are linked to higher-level cravings.\nHowever during the luteal phase -- after a woman ovulates and before her period -- only one area of the brain was activated by images of cigarettes and smoking.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not consult with independent sources. A brief talk or email exchange with any qualified expert would\u2019ve shot down most of the inflated claims made in this story.\u00a0Any journalist who doesn\u2019t know where to turn for independent sources could access our List of Industry-Independent Experts.", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Everyone quoted in the article is an advocate of efforts to teach, learn and use CPR in bystander situations. Those perspectives are fine, but the story should have at least quoted or cited some source about the risks, downsides, and low survival rate of those who undergo CPR. The conflicts of interest are apparent: those quoted are all survivors, survivor advocates, or CPR trainers.", "answer": 0}, {"article": "\"It's pretty encouraging,\" said Robert A.\n\"These are children who could have died from a teaspoon of milk before,\" Wood said.\nIf she were even touched by someone with milk on their hands, she would break out in hives and a bright red rash.\nShe eats any food anybody else can,\" Lissa Roberts said.\nAfter between about nine months and two years, about half of the children could safely consume as much milk or food containing milk as they wanted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A broad range of experts in the field and a funding agency spokesperson were all quoted as sources of information for this story.\u00a0 ", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Botox injections may provide some relief from arm tremors caused by multiple sclerosis, according to a small study published Monday.\nIn contrast, there were no improvements after the placebo injections.\nThe study\u2019s lead researcher agreed on the need for more work.\nThat will vary from patient to patient, depending on how many injections are needed per treatment.\nTheir ability to write and draw a straight line had also improved by week six, and the benefits were still there at week 12.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Actually, most of the quotes came from an independent perspective.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story could have done a better job with sources. In the original AP story there were two sources quoted, one of whom works for the CDC which issued the recommendations, and the other is independent.\u00a0 But the NY Daily News cut out the independent source interview. The story might have included a pulmonologist not on the recommending panel, or at a primary care physician, to give perspective on the current evidence and clinical implications of vaccinating 31 million adult smokers while providing smoking cessation counseling. ", "answer": 0}, {"article": "Currently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\nIt turned out that gene activity in the PI3K pathway was \"off the chart\" in smokers with lung cancer versus those without the disease.\n\"This drug inhibits the pathway that's activated in smokers.\nOnly 15 percent of patients are still alive at five years, said Nana-Sinkam.\n\"We have identified a marker for an early risk of developing lung cancer.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barely satisfactory.\u00a0 One independent expert quoted \u2013 but one whose quote offered no analysis.\u00a0 Financial interest of the lead investigator is mentioned.\u00a0 ", "answer": 1}, {"article": "Researchers have found that delivering a fecal microbiota transplant (FMT) in a pill\u2014a poop pill, basically\u2014is no worse than a similar procedure done with a colonoscopy.\nThough the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.\nOne recent, small study found that even stool samples that are entirely free of bacteria can be effective, perhaps because there are non-bacterial organisms that also help.\nTwo-thirds of the 57 patients who got the pills said their experiences were \u201cnot at all unpleasant,\u201d while just 44 percent of the 59 patients who received the FMT via a colonoscopy could say the same.\n\u201cWe still don\u2019t understand what\u2019s going on, and in these other conditions it\u2019s not as clear-cut that the disturbance in the bacterial composition is the cause,\u201d Kao said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include comments from an independent source unaffiliated with the research. But, it doesn\u2019t specify that the source has received research money from a drug company that\u2019s developing microbiome drugs.", "answer": 0}, {"article": "It is sort of a window into the lung.\u201d\n\nCigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nThe main gene is called PI3K and it affects a pathway of other genes, Bild, Avrum Spira of Boston University and colleagues reported.\n\u201cWhether it is going to save millions of people, who knows?\u201d\n\nSpira said he is working with Boston-based Allegro Diagnostics, which is halfway through a 60-patient clinical trial of the test.\n\u201cEven in normal cells or premalignant cells prior to cancer development we see this pathway being turned on,\u201d said Andrea Bild of the University of Utah, who worked on the study published in the journal Science Translational Medicine.\n\u201cWe found this certain pathway, PI3K, was turned on in patients that had lung cancer as opposed to patients that had other problems,\u201d Bild said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "       \n \nNo independent experts were interviewed for this story. Furthermore, the story failed to mention that Dr. Spira, one of the study\u2019s authors, is the founder of Allegro Diagnostics and currently sits on the Board of Directors and serves as a consultant. The story only says he is \"working with\" the company. What does that mean? \n ", "answer": 0}, {"article": "TUESDAY, Nov. 27, 2018 (HealthDay News) --What if a simple zap to the spine could relieve the debilitating lower back and leg pain brought on by a herniated disk?\n\"Without inflammation the pain fades, and the body starts a self-healing process that allows for complete resolution of the disk herniation in a large proportion of patients.\"\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\nSuch is the promise of \"pulse radiofrequency\" therapy (pRF), which sends inflammation-reducing pulses of energy to nerve roots in the spine, a new study claims.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Laudably, the story contains cautionary comments from a physician who was not involved with the study. He points out that most people with back pain \u201cimprove with time and exercise alone,\u201d and \u201cit remains an open question as to whether the pRF procedure really cured the condition.\u201d\nWe wish some of the cautions had been placed higher in the story.\nThe story did not mention conflicts of interest, and we could not find any that the authors have disclosed.", "answer": 1}, {"article": "And will they change the quality of sleep in any way?\nUslaner and his colleagues investigated a compound called DORA-22, which has the same mechanism of action as suvorexant, to see how it fared alongside not only Ambien and Lunesta but also diazepam (Valium) in rats and rhesus monkeys.\nThe appeal of orexin antagonists, said Dr. Michael Thorpy, director of the Sleep-Wake Disorders Center at Montefiore Medical Center in New York City, is that they \"target a system that's more specific for sleep.\"\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\nThis is the first time in years that scientists have targeted a totally different receptor in the quest to combat insomnia, said Dr. Alexandre Abreu, co-director of the UHealth Sleep Center at the University of Miami Miller School of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story reports that the researchers work for Merck, the maker of a drug similar to the one they tested. It also includes comments from two independent sources. This story does a better job of providing independent perspectives than the Reuters story we also reviewed. But neither unaffiliated expert points out the study design and the inherent liabilities in interpretation to humans.", "answer": 1}, {"article": "\"They did show a higher recurrence or progression rate with endometrial cancer than with AEH and that is consistent with other data,\" said Bakkum-Gamez, who added that the IUD method would not be appropriate for later-stage cancers, which tend to be more aggressive.\nNine of the women in the study successfully delivered babies.\nNo adverse effects from treatment were noted, according to the researchers, who declared no conflicts of interest.\nOral hormone treatment to slow down the cancer's growth is a systemic therapy, however, and can have adverse side effects such as skin rashes, nausea and vomiting, headaches and abnormal uterine bleeding, according to background material accompanying the study.\nBakkum-Gomez has also used the method in her practice and is conducting a study of the IUD, which was originally designed as a contraceptive device, for this purpose.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several independent experts and notes that none had a conflict of interest.", "answer": 1}, {"article": "Generally, massage is not covered by insurance, Medicaid or Medicare.\nThe massage therapist designed and provided a series of 10 massages -- at no cost to the patient -- in a clinical treatment environment, mimicking the experience of people who choose to seek massage therapy in the real world.\nAmong the study's findings:\n\nAdults in the baby-boom and older generations tended to be much more likely to experience clinically meaningful changes.\nThe study, \"Real-World Massage Therapy Produces Meaningful Effectiveness Signal for Primary Care Patients with Chronic Low Back Pain: Results of a Repeated Measures Cohort Study,\" was published online March 14 in the journal Pain Medicine.\nINDIANAPOLIS -- In the first study of its kind, researchers found real-world massage therapy to be an effective treatment for chronic low back pain.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not give us any information about who funded the study. We should be told who funded the study and if there are any conflicts of interest for the authors or their institutions.", "answer": 0}, {"article": "The study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\n\"I think our results show promise for this population, however this study is just a beginning.\nUnfortunately, about 40 percent of adolescents do not respond to their first intervention and only half of nonresponders respond to the second treatment, according to the researchers.\nFinding the right treatment is critical to allow the restoration of healthy brain development and prevent negative outcomes like chronic depression, disability and suicide.\"\nHowever, relatively little research has been conducted into ketamine's antidepressant effects in adolescents.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted a researcher unaffiliated with this study.\u00a0 We could find no conflicts of interest.", "answer": 1}, {"article": "The findings don't confirm that the ancient Chinese discipline relieves hot flashes, and only 14 men participated in the study, which was conducted by researchers at New York Methodist Hospital and Weill Cornell Medical College of Cornell University.\n\"It is a definite nuisance.\nTheir reported level of hot flashes dropped markedly.\nHormone therapy designed to reduce levels of testosterone in the body is one of the standard treatments for prostate cancer.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert was interviewed.", "answer": 1}, {"article": "The signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe study quotes the author of an editorial that also appears in the issue of the Archives of Neurology that carries the study article. The story notes that the study author who is quoted developed the experimental test and works for a biotech company. It also points out that the study was funded by a partnership that includes private interests.", "answer": 1}, {"article": "Type 2 diabetes is caused by the body\u2019s in ability to break down sugars from the diet.\nMost importantly, 46% of the people in the diet group went into remission with their diabetes, compared to just 4% in the control group.\nThe current study takes that work a step further and shows that it\u2019s possible to actually reverse the disease in people who have been diagnosed.\nIf more people can benefit from losing weight alone, then that would mean less cost to the health care system, as fewer people will suffer the serious complications of advanced disease, which can include heart problems, neuropathy, vision issues and even amputations.\nStudies suggest that people living with diabetes for more than 10 years, for example, may not be able to rely on weight loss alone to push them into remission.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a study author but no other sources. We think readers deserve to hear from experts not involved with the study at hand to provide context about the findings.", "answer": 0}, {"article": "\u2022 3 diet shakes per day and 240 grams of non-starchy vegetables taking in between 600 and 700kcal a day for 8 weeks\n\u2022 volunteers then gradually returned to eating normal food over the next two weeks with very careful instruction on how much to eat\n\u2022 volunteers were seen once a month and supported with an individualized weight maintenance programme over the next 6 months\n\u2022 to keep weight steady after the weight loss, they were eating around one third less than before the study\n\nAllan Tutty, 57, from Sunderland, transformed his health by taking part in the study.\nThis will examine how successfully people can reverse their diabetes through weight loss simply under the care of their family doctor and nurse.\nThe team were able to identify in advance participants who would not respond to adequate weight loss by reversing their diabetes as at the start they had almost absent insulin production from the pancreas.\nBut it is too early to regard this as suitable for everyone.\nThough the volunteers lost weight they remained overweight or obese but they had lost enough weight to remove the fat out of the pancreas and allow normal insulin production.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does identify multiple funding sources and there is no suggestion of any conflict of interest.", "answer": 1}, {"article": "Folic acid -- a synthetic version of folate found in many supplements and multivitamins -- has been shown to lower homocysteine in previous studies, but its effect on disease risk is disputed.\n\"A healthy diet likely remains important,\" Seshadri says.\n\"The role of supplementation remains unclear.\"\n\"Good nutrition should minimize the risk of Alzheimer's disease, but we can't say that any specific food has been proven to reduce this risk.\"\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "For more information, visit http://www.\n\"Prostate cancer still represents one of the main causes for cancer-related deaths among men,\" said Matthias Eder, PhD, co-author of the study and a researcher in the division of radiopharmaceutical chemistry at the German Cancer Research Center in Heidelberg, Germany.\nThe PSMA-inhibiting theranostic agent, called PSMA-617, is still in its initial stages, but it could be ideal for the treatment of patients with hormone-refractory prostate cancers, which are notoriously difficult to control and linked to poor prognosis.\nThe current clinical methods are not sensitive enough for detecting disease beyond the prostate, but we are convinced that this novel theranostic radiotracer represents a significant step forward that could have a major impact on the future of prostate cancer care.\"\nScientific Paper 63: \"PSMA-617 - a novel theranostic PSMA inhibitor for both diagnosis and endoradiotherapy of prostate cancer,\" M. Benesova, M. Sch\u00e4fer, U. Bauder-W\u00fcst, K. Kopka, M. Eder, Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany; C. Kratochwil, A. Afshar-Oromieh, W. Mier, U. Haberkorn, Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; SNMMI's 62nd Annual Meeting, June 6-10, 2015, Baltimore, Md.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of funding for this work, so it is difficult to determine if there is any conflict of interest.\u00a0 Funding is listed in the abstract and fairly clearly shows that there is no conflict of interest, but that is impossible to tell from the release.", "answer": 0}, {"article": "Psoriasis is an immune-mediated disease that causes itchy, dry and red skin.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\n\"Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients,\" said first author Kenneth Gordon, MD, professor in Dermatology.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\nAt week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the release clearly notes that the study was funded by the company that manufactures guselkumab, and that the study\u2019s lead author is a former paid consultant for the company, it fails to tell readers that the company was actively involved in the study. The journal article points out that Janssen Research and Development collected and analyzed the data. What\u2019s more, \u201cAll the authors collaborated on writing the manuscript, with the assistance of professional medical writers employed by Janssen, and made the decision to submit the manuscript for publication.\u201d That intimate level of involvement should have been made clear in the release.", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had no independent sources. It also didn\u2019t disclose the conflict of interest of Dr. Paul Aisen, who\u00a0has received money from multiple drug companies, including the ones discussed in this piece.", "answer": 0}, {"article": "WEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\n\"We are not currently performing any studies with Chantix, although other groups are actively pursuing this line of research with a view to developing Chantix as an aid to people wanting to quit or cut down their drinking,\" Childs said.\nThe results of the new study were released online in Alcoholism: Clinical & Experimental Research prior to publication in the May print issue.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nRecently, the drug was linked to a small but significant risk of heart attack and stroke among people with pre-existing heart disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include an independent source. There was no disclosure statement included with the preview copy of the research article, so it is not known whether any of the researchers have ties to Pfizer (the maker of Chantix) or other pharmaceutical companies in this area.", "answer": 1}, {"article": "Liao feared that cutting open Holmes\u2019 chest and sternum for an open bypass surgery would disrupt his rehabilitation from the cardiac arrest and delay his plans to return to athletics.\nThe learning curve for cardiac surgeons was too steep, though, and the system\u2019s tools weren\u2019t as useful for heart surgeries as they were for other procedures, said Dr. Goya Raikar, a cardiothoracic surgeon at Regions Hospital in St. Paul.\nThe number of da Vinci robots has doubled in Minnesota in less than two years, with two at the university and four at the Mayo Clinic in Rochester.\n\u201cThe system and instruments have kind of caught up to the point where heart surgeons are taking a close look at this now,\u201d he said.\nThe robotic systems come with million-dollar price tags and are used for a limited number of surgeries \u2014 mostly the removal of cancerous prostates in men or uteruses in women.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes two physicians, both of whom use the machine\u2013and work at hospitals that have invested in the machines. \nThe reporter should have talked to at least one surgeon who has declined to use the device, and one independent researcher with no conflict of interest who could summarize the findings of safety and efficacy.\nFinally, there is some federal data about negative outcomes with the device\u2013including at least one unnecessary death early in the device\u2019s development\u2013that should have been drawn on.\u00a0", "answer": 0}, {"article": "Researchers here quantified the detection of cervical precancer and cancer by cotesting compared with HPV testing alone at Kaiser Permanente, where 1,208,710 women have undergone triennial cervical cotesting since 2003.\nThe HPV test captures the known cancer causing viruses, but there are gynecologists who believe that there may be unknown cancer causing viruses and so continue to do the Pap smear (plus HPV testing).\nAn HPV test, in which doctors test a cervicovaginal specimen for the presence of the nucleic acids of carcinogenic types of HPV, is more sensitive than the Pap test (a microscopic examination of exfoliated cells) for detection of precancers.\nThe accumulated evidence supports inclusion of HPV testing in screening; thus, the main choice moving forward is between cotesting and primary HPV testing alone.\nThus, if a single screening method were chosen to complement HPV vaccination, primary HPV testing likely would gradually supplant the Pap test.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder (NIH/National Cancer Institute) is listed on a sidebar of EurekAlert! where the release is hosted. We encourage releases to also include funders in the release itself. There do not appear to be any conflicts.", "answer": 1}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nAllergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model \u2013 Growth Pharma.\n\"Interestingly, neurostimulation has been used as an approach for a wide variety of disorders for more than 30 years.\nWARNINGS \n\nDo not apply stimulation around electronic monitoring equipment (eg, cardiac monitors, ECG alarms), in the bath/shower, while driving, operating machinery, during activity in which sneezing/watery eyes may cause risk, areas other than the nose, within 3 feet of shortwave or microwave therapy equipment, around flammable anesthetics mixture (air, oxygen or nitrous oxygen).\n\"As an innovator in eye care, we are continually looking for new products to offer through our portfolio, and TrueTear\u2122 represents the next step forward.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although readers will assume that Allergan (and Oculeve, which first developed the device before it was bought by Allergan) funded the studies, the release includes a quote from a university professor without disclosing that he serves as an advisor or consultant to Allergan and makes paid speeches on behalf of the company. (See \u201cFaculty and Disclosures\u201d link in this Medscape CME article.)", "answer": 0}, {"article": "The 2,000-year-old treatment is widely used around the world, according to the National Center for Complementary and Alternative Medicine (NCCAM), part of the National Institutes of Health (NIH).\nResearchers knew who was receiving sham treatment, but the women, who completed questionnaires detailing the extent of their hot flashes, did not.\nThe study of acupuncture as a remedy for hot flashes was sparked by reports from women who had undergone the ancient Chinese therapy for other problems and reported that their hot flashes seemed to moderate.\n\"We were hoping for something better,\" she said.\nSome herbs and supplements seem to work, she added, but improvement has proven to be temporary.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Article cites an author of the study, another expert, and a National Institutes of Health consensus document. ", "answer": 1}, {"article": "MONDAY, Sept. 27, 2010 (HealthDay News) -- In a head-to-head comparison of drug-coated stents -- the metal mesh tubes used to keep clogged arteries open -- the well-established model using the drug sirolimus came out on top, South Korean researchers report.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\n\"In this large-scale, practical randomized trial, the use of zotarolimus-eluting stents resulted in similar rates of major adverse cardiac events compared with sirolimus-eluting stents and in fewer major adverse cardiac events compared with paclitaxel-eluting stents at 12 months,\" the researchers concluded in their report.\nThe number of heart attacks and deaths was about the same in each group, but the rate of blood clots in the stents was significantly lower with sirolimus-eluting stents, Park's team also found.\nThe researchers found that 10.2 percent of the patients who received zotarolimus-coated stents suffered a major adverse cardiac event, compared with 8.3 percent of the patients who received sirolimus-coated stents and 14.1 percent of those with paclitaxel-coated stents.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One source, Dr. Fonarow, was apparently not affiliated with the study. We appreciated his placing the results in context with prior research and on clinical decision-making.\u00a0Google tells us that he has a\u00a0financial relationship\u00a0with the company that makes zotarolimus-coated stents. But given the fact that his quotes\u2014and the study\u2014are not in favor of zotarolimus, perhaps the lack of this disclosure is excusable.\nOne key conflict of interest, study funding from a stent manufacturer, was identified. However, we fail the article on this criterion because it neglects to mention that the researchers disclosed a web of financial relationships with literally all the stent manufacturers. We count 9 financial relationships with Cordis, who makes the sirolimus-coated stent, which came out \u201con top\u201d in this article.", "answer": 0}, {"article": "SUNDAY, March 21, 2010 (HealthDay News) -- For the first time in humans, scientists have successfully used a gene-manipulation therapy to enter tumor cells and block the production of toxic proteins that are causing cancer, researchers report.\n\"This will run its course.\n\"This is one step away from getting into the actual DNA.\"\n\"This is something we've been waiting to see,\" he continued.\nIt's potentially huge.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources were quoted. ", "answer": 1}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There appear to be no outside sources used in this story.\u00a0 All the information comes from the FDA. However, because of that, there is no conflict of interest as the drug manufacturer/distributor is identified, but no information apparently comes from them.\nIt is important to remember here that the role of the FDA is to approve based on effectiveness and safety and the bar for both in a disease like melanoma is low. How clinically useful this drug will prove to be is open to question and it would have been nice to hear from some independent oncologists about that.", "answer": 0}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story didn\u2019t settle for the manufacturers\u2019 claims.\u00a0 It turned to four other sources.", "answer": 1}, {"article": "That's why the device requires training every time Burkhart uses it.\n\"This technology is possible because there's about 50 years of basic neuroscience that has been looking at how signals in the brain encode information about movement,\" Dr Andrew Jackson, a neuroscientist at Newcastle University who was not involved with the work, told BuzzFeed News.\n\"Brain signals change from day to day (even hour to hour), the signals may be different depending on context (am I trying to lift a full or an empty glass, do I watch someone draw or do I want to draw myself), and brain signals change while we learn a new task,\" he told BuzzFeed news.\n\"We have to be realistic about this, there's still quite a long way towards turning this into something that would be feasible for widespread use in large numbers of people,\" Jackson said.\nThe study builds on previous work in which humans have been able to move computer cursors and robotic arms using their own brain signals, and a study in which monkeys with paralysed arms were able to move them again thanks to a similar intervention.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes strong context and cautionary statements from two independent sources. However, we cannot give it a Satisfactory rating because it doesn\u2019t tell readers that the researchers have an interest in patents for the hardware and software they are developing. These financial interests were clearly noted in the Nature journal article and should have been included in the story.", "answer": 0}, {"article": "Now, before anyone goes dumping tons of extra cinnamon in their egg nog in hopes of keeping holiday-season pounds at bay, Wu cautioned that further study is needed to determine how best to harness cinnamaldehyde's metabolic benefits without causing adverse side effects.\nThat fat could then be used by the body in times of scarcity or in cold temperatures, which induce adipocytes to convert stored energy into heat.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\n\"Cinnamon has been part of our diets for thousands of years, and people generally enjoy it,\" Wu said.\nThe research was supported by the Human Frontier Science Program, Edward Mallinckrodt Jr. Foundation, National Institutes of Health and American Heart Association.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are clearly included in the news release. There are no conflicts of interest listed in the news release or study.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - There may be a seed of truth amidst the many health claims for pomegranate juice, researchers from Israel said Thursday, at least for kidney patients on dialysis.\nThey also made fewer trips to the hospital.\nAntioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\n\u201cThis study does not demonstrate anything special about pomegranate juice,\u201d she told Reuters Health in an e-mail.\nBy comparison, that number would be nearly 11 in patients not drinking the juice.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from two skeptical independent experts made this a solid piece.", "answer": 1}, {"article": "For more information visit http://www.\nSome of the data was presented at 16:25 CEST today (Sunday) at the European Society for Medical Oncology 2016 Congress in Copenhagen.\nA total of \u00a362 million is being provided over five years, to support pioneering research work, and is being shared out over eight different cancer themes.\nSince 2004, the hospital's charity, The Royal Marsden Cancer Charity, has helped raise over \u00a3100 million to build theatres, diagnostic centres, and drug development units.\nThe Royal Marsden, with the ICR, is the only National Institute for Health Research Biomedical Research Centre for Cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes clear that the study was funded by Bristol Myers Squibb. That\u2019s good. The release does not, however, tell readers that some of the study authors received personal fees from Bristol Myers Squibb, in addition to the grant funding. That information can be found in conflict-of-interest disclosure documents on NEJM\u2018s site.", "answer": 0}, {"article": "\u201cHospitalization is often necessary when patients start to retain fluid, develop congestion and experience shortness of breath.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\nEach year, approximately 55,000 patients receive innovative and compassionate care from multidisciplinary teams in the Peter Munk Cardiac Centre, and the Centre trains more cardiologists, cardiovascular surgeons and vascular surgeons than any other hospital in Canada.\n\u201cNever before have we had the ability to obtain a patient\u2019s accurate lung pressure data while they are outside the hospital,\u201d said Meredith Linghorne, nurse practitioner, Peter Munk Cardiac Centre.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We found no conflicts of interest associated with this news release. The release discloses the fact that the CardioMEMS implantation procedure was funded by the Ted Rogers Centre for Heart Research.\nWe give the news release a Satisfactory rating here.", "answer": 1}, {"article": "As Albert, a pseudonym for an AA member in Georgia, previously told me, \u201cThere\u2019s just not a lot of widely advertised options available.\u201d AA and 12-step treatment are \u201cthe most well-known and most recommended option, so that\u2019s kind of where you tend to go.\u201d\n\nZemore\u2019s study begins to peel away at this problem.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\nThere\u2019s very few places in medicine where you do.\u201d So there need to be as many alternatives as possible.\nThe research is by no means the last word on this question \u2014 Zemore characterized the study as the beginning of a deeper evaluation into AA alternatives.\n\u201cThat suggests that people with less commitment to lifetime total abstinence are more likely to participate in SMART and LifeRing than they are to participate in 12-step groups,\u201d Zemore said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an expert source who was not affiliated with the research and who provides useful context about key limitations of this study. It doesn\u2019t appear that there are any undisclosed conflicts of interest.", "answer": 1}, {"article": "The other groups showed no significant change.\nThe study was small, involving 50 men and women ages 50 to 72 who ranged from normal weight to overweight.\nEating fewer calories may lead to better memory, a new study says.\nDr. Fl\u00f6el said the memory improvement might be linked to a decrease in insulin and inflammation in the calorie-restricted participants, who lost four to seven pounds.\nMembers of a second group kept their calories the same but were instructed to increase the unsaturated fat (healthy fat) they ate by 20 percent.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed one of the study researchers, a lead researcher in a related study and one independent expert. \n\u00a0", "answer": 1}, {"article": "Copyright 2012 The Associated Press.\nThere also was a trend toward fewer cancer deaths among multivitamin users, but the difference was so small it could have occurred by chance alone.\nYet no government agency recommends their routine use \"regardless of the quality of a person's diet,\" says a fact sheet from the federal Office of Dietary Supplements.\nThe result is a surprise because many studies of individual vitamins have found they don't help prevent chronic diseases and some have even caused problems.\nSome fads, such as the antioxidant craze over vitamins A and E and beta-carotene, backfired when studies found more health risk with those supplements, not less.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We hear from an expert who wan\u2019t involved with the study, and we receive a complete description of the study\u2019s funding\u00a0sources. The story notes that while NIH paid for most of the study, Pfizer supplied the pills.\u00a0That\u2019s a detail we didn\u2019t hear about in the competing Reuters piece.", "answer": 1}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Besides the one reference to Kaiser Health News, all the sources had connections to the patient.", "answer": 0}, {"article": "The World Journal of Surgery article, by lead author breast surgeon Michael J.\n\"Through our experience with this marker, we've observed that its use results in less radiation dose to the patient compared to whole breast radiation, plus a better overall cosmetic outcome,\" said Dr. Cross, a nationally known breast surgeon at Breast Treatment Associates, in Fayetteville Ark.\nThe article also noted that there was a shift during the three-year course of the study toward increasing use of hypo-fractionated radiation methods.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nIt is the first and only device that identifies in a reliable way the 3-D region where the tumor was removed.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news is provided by Focal Therapeutics, maker of the implant. \u00a0There is no mention in the news release of any potential conflict of interest, but the published study noted one of the authors had a financial arrangement with Focal.", "answer": 0}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc\u2019s treatment for a side effect caused by a commonly prescribed Parkinson\u2019s drug, sending the shares of the drugmaker soaring in after-market trading.\nThe long-acting therapy is taken once-daily at bedtime.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nThese patients have little recourse, other than opting for deep brain stimulation, a surgical procedure that involves blocking electrical signals from targeted areas in the brain.\nFluctuating levels of levodopa result in erratic periods of muscular control and involuntary movements throughout the day, disrupting activity at least half a dozen times a day.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Outside sources not connected to the study would have been a great addition to the story, but there were none.", "answer": 0}, {"article": "MORE: Losing Focus?\nIn fact, in 2005, more than 500 brain researchers signed a petition (albeit an unsuccessful one) to protest a scheduled lecture on the neuroscience of meditation by the Buddhist spiritual icon, the Dalai Lama, at a major conference organized by the Society for Neuroscience.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\nStudies Say Meditation May Help\n\n\u201cThe main finding [of our research] is that, added on top of usual medical care, intervention with a mind-body technique \u2014 transcendental meditation \u2014 can have a major effect on cardiovascular events,\u201d says Robert Schneider, lead author on the study published in Circulation: Cardiovascular Quality and Outcomes and a professor at the Maharishi University of Management, an institution in Iowa that was founded by the creator of transcendental meditation.\nMORE: Medical Meditation: Say Om Before Surgery\n\nAfter roughly five years of follow-up, the researchers found a 48% reduction in the overall risk of heart attack, stroke, and death from any cause among members of the meditation group compared to those from the health education group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only interview source for this story one of the study authors, Dr. Robert Schneider.\u00a0Considering that Dr. Schneider works at an institution\u00a0founded by the creator of transcendental meditation (Maharishi College of Perfect Health), his objectivity on this issue is certainly open to question.\u00a0The story could have addressed any\u00a0concerns about\u00a0objectivity by balancing Dr. Schneider\u2019s\u00a0comments with those\u00a0from an independent cardiology expert.", "answer": 0}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story should have mentioned that Dr. Kuehl appears on the Cherry Marketing Institute\u2019s \u201cpower team.\u201d\nAnd there was no independent perspective quoted.\u00a0 Only one author saying his work \u201ccould someday provide an alternative treatment\u201d and another author saying \u201cthere are some interesting and potentially exciting results on the horizon. Stay tuned.\u201d", "answer": 0}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did state doctor affiliations to the company making the device and also quoted some people not affiliated with the company.", "answer": 1}, {"article": "Previous reports22,23 of the overall randomized clinical trial found locoregional control and survival advantages associated with the addition of cetuximab to radiotherapy.\nHistorically, locoregionally advanced squamous cell cancers of the larynx or hypopharynx have been treated with surgical resection, usually involving laryngectomy with or without postoperative radiotherapy.1 Although laryngectomy is an effective treatment, investigators have sought therapeutic strategies that result in voice preservation.\nIn a recent trial from France, 269 patients were queried about the treatment choices they might make if they faced the diagnosis of advanced laryngeal cancer.30 Only 29% stated that they would not consider options with a lower chance of cure if told that the best option, with respect to survival, was total laryngectomy.\nInvestigators have reported that poor follow-up may contribute to the potential for larger and less curable recurrences, and surgeons experienced with radiotherapy with salvage surgery need to be involved as early as possible.20,21\n\nThe analysis described in this report was performed to assess the laryngeal preservation rates of patients with locoregionally advanced laryngeal and hypopharyngeal cancers who were entered into a randomized clinical trial of cetuximab and radiotherapy (CRT) compared with radiotherapy alone.22,23 This group of patients represents a subgroup (168 patients) of a larger population (424 patients) that also included patients with oropharyngeal cancers.\nEven when the patient achieves a certain level of comfort with various techniques of artificial speech,27 the ability to communicate with others is hampered.26,28,29 Investigations have explored both the patient\u2019s and the interviewer\u2019s perceptions of the patient\u2019s difficulty with communication after laryngectomy.26 Of interest, the interviewers perceived the patients\u2019 impairment with communication as a much greater infringement on quality of life compared with the patients\u2019 perceptions.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release tells readers that the work was funded by Eli Lilly and Company, but refers readers to the journal article for information about financial disclosures, potential conflicts of interest, etc. This is not okay, for two reasons. First, while the release mentions Eli Lilly\u2019s funding, it doesn\u2019t make clear Lilly\u2019s financial ties to cetuximab. Lilly manufactures cetuximab and receives royalties on Erbitux worldwide (though it is marketed by different companies, depending on where it is being sold). In short, Lilly has a vested interest in seeing an increase in cetuximab use (the drug reportedly brought in $723 million in 2014 \u2014 in North America alone). Second, many readers, possibly most readers, may not have access to the journal article. And if an institution knows that information is worth mentioning to readers (such as whether researchers had conflicts of interest), then an institution should not make readers put in extra legwork to find that information. And there is certainly relevant information to share here. The lead author reported working as a consultant for Lilly. Two co-authors are Lilly employees. A third co-author is a former Lilly employee and owns Lilly stock. And a fourth co-author works for Merck KGaA, which markets cetuximab outside of North America. In other words, five of the nine authors have clear conflicts of interest that are not disclosed in the release.", "answer": 0}, {"article": "Wine rounds out the list of of 10 \"brain healthy\" food groups that help protect against Alzheimer's: green leafy vegetables, other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil and wine.\nThe study, published in the journal Alzheimer's & Dementia, looked at more than 900 people between the ages of 58 and 98 who filled out food questionnaires and underwent repeated neurological testing.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nA new study by researchers at Rush University Medical Center in Chicago shows a diet plan they developed -- appropriately called the MIND diet -- may reduce the risk of developing Alzheimer's disease by as much as 53 percent.\nBut the MIND diet helped slow the rate of cognitive decline and protect against Alzheimer's regardless of other risk factors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There appear to be no independent sources used in this story.\u00a0 The paper indicates that there is no conflict of interest for the authors, so no mention of conflict is acceptable. A comment by an expert not affiliated with the study would have provided context.", "answer": 0}, {"article": "Down the road, the \"fantasy\" is that asymptomatic people will be able to get a biomarker test to determine whether they'll one day get Alzheimer's, but that's not possible right now, he adds.\nClinical trials can better focus their efforts if patients are known to be in the early stages of Alzheimer's.\nIn looking for treatments, however, researchers depend on people's willingness to contribute to science.\nBut it's too early to use this as a diagnostic tool in clinical settings, says Brickman.\nCheck it out if you're interested in finding a trial for yourself or someone you care about.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert\u2019s comments added needed perspective to the findings.", "answer": 1}, {"article": "When it's functioning properly, BRCA actually helps repair damaged DNA and prevents tumors, but when BRCA1 and BRCA2 go awry, they encourage breast cancers.\nIn addition, several ongoing studies are looking at combinations with PARP inhibitors \"to try to expand who may benefit or lengthen how long they may work,\" Litton said.\nThe trial results are preliminary, as talazoparib has not yet been approved by the U.S. Food and Drug Administration.\nThe trial was funded by drug maker Pfizer, and the results were published Aug. 15 in the New England Journal of Medicine.\nIn the current trial, the women who were randomly selected to receive talazoparib had a higher response rate to treatment than women who received standard chemotherapy: 63 percent versus 27 percent, the researchers found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentions the study was funded by the drugmaker, Pfizer. It also clearly identifies one source, Jennifer Litton, as the lead researcher on the story.\nThe other quoted source, Marisa Weiss was not involved in the research. However, both Weiss and the organization she works for, Breastcancer.org, have received money from Pfizer. This was not disclosed in the story.", "answer": 0}, {"article": "The screening phase of the trial lasted about seven years.\nDr. Stamatia Destounis, a radiologist at Elizabeth Wende Breast Care in Rochester, New York, who was not involved in the study, said radiologists have been quoting results of the Swedish study for years and the new findings show breast cancer screening is \u201ceven more of a benefit than we understood.\u201d\n\nShe said sweeping changes in the U.S. screening guidelines two years ago that scaled back recommendations on breast cancer screening caused a lot of confusion among doctors and patients about the benefits of mammograms.\n\u201cThis indicates that the long-term benefits of screening in terms of deaths prevented are more than double those often quoted for short-term follow-up.\u201d\n\nThe new data adds to evidence on the long-term benefits of regular mammography screening.\n\u201cWe saw the actual number of overdiagnosed cases was really very small \u2014 less than 5 percent of the total,\u201d Robert Smith, director of cancer screening at the American Cancer Society and one of the study\u2019s authors, said in a telephone interview.\nMany groups, including the American Cancer Society, have stuck by their long-standing recommendations of a yearly breast exam for women starting at age 40, stressing that the breast X-rays have been proven to save lives by spotting tumors early, when they are most easily treated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included a quote from a radiologist not involved in the study, but one could argue that a radiologist has a vested interest in mammography screening. (And why/how was that radiologist chosen?) Additional perspectives would have been welcomed. For instance, why was no one from the U.S. Preventive Services Task Force asked to comment? That is difficult to understand.\u00a0 And while the study authors had no potential conflicts of interests to disclose, it\u2019s well known that some of the study authors are long-time proponents of mammography screening and this is worth mentioning.\n", "answer": 0}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two clinicians, both of whom are authors on the current study. The story should have quoted other clinicians who are not affiliated with the study who could have provided some perspective.", "answer": 0}, {"article": "Abbott Diagnostics developed both the new and the conventional troponin tests used in the study.\nThe issue with available troponin testing has been that they must be repeated two more times over the next 12 to 16 hours for accurate readings.\nTUESDAY, Dec. 27, 2011 (HealthDay News) -- A new test measuring levels of troponin I in the blood may help determine whether someone is really having a heart attack earlier than is currently possible.\nResearchers led by Dr. Till Keller at the University Heart Center in Hamburg, Germany, compared the new highly sensitive troponin I test with the current test and other blood markers for heart attack among 1,818 people who showed symptoms of a possible heart attack.\n\"We need a blood test that can tell people when they walk in or soon thereafter that they are having a heart attack because the sooner you make the diagnosis, the sooner you can start the right therapy.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentioned that the study was funded by two pharma companies but it did not include any of the individual disclosures included in the journal article itself.\nAnd, in terms of sourcing, while the story did include quotes from two independent physicians, neither of them directly addressed the quality of the evidence.\nOne said \u201cwe can rule out heart attacks more quickly with the new test\u201d but it wasn\u2019t clear if she had used the test or if she was commenting on the data reported. So we don\u2019t know why she was used as a source.\nThe other spoke in only very general terms about the ultimate goal of such research and about the need for such a blood test \u2013 but nothing about the evidence itself.", "answer": 0}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly states who funded the studies, and what that organization\u2019s long-term goals are. Further, the story clearly identified individuals quoted in the story who have ties to the studies or the funding organization. Lastly, the story incorporates input from an independent expert.\nHowever, the story would have been stronger if there had been a skeptical take on the research, which saw\u00a0in some other coverage, such as this New York Times piece.", "answer": 1}, {"article": "ROCHESTER, Minn. \u2014 Can estrogen preserve brain function and decrease the risk of Alzheimer\u2019s disease when given early in menopause?\nResearchers investigated the brain amyloid deposition in 68 women ages 42 to 59 who participated in the Kronos trial during this critical window.\nA rapid decline in estrogen with menopause may be associated with an increased risk of Alzheimer\u2019s disease risk in women.\nOf the 68 women, 21 received estrogen via a skin patch, 17 received estrogen orally and 30 received a placebo.\nThe researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are identified, and\u00a0the single scientist\u00a0in the release\u00a0is clearly identified as the study\u2019s lead author.", "answer": 1}, {"article": "The researchers, led by Dr. Gabriele Di Lorenzo of the University of Palermo, describe the benefits as \u201cmodest.\u201d\n\nIn an email, Di Lorenzo told Reuters Health that the findings suggest that sublingual immunotherapy is \u201chighly effective in many, but not in all patients.\u201d He said that more work is needed to identify which patients might be most likely to benefit.\nBut longer term data are not yet available.\nThe shots help prevent hay fever symptoms by exposing people, over time, to small amounts of the pollen to which they are allergic, essentially desensitizing the immune system to the allergen.\nIn an interview, he noted that antihistamines reduce symptoms by about 12 percent to 15 percent, on average.\nAllergy shots are typically given weekly at first, followed by monthly injections over several years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nThe story includes an interview with an allergist not affiliated with the research.\u00a0 \n", "answer": 1}, {"article": "The findings build on a 2015 UCLA study that demonstrated that both green tea and black tea helped prevent obesity in mice that consumed a high-fat, high-sugar diet.\nIn the mice that consumed either type of tea extract, there was less of the type of bacteria associated with obesity and more of the bacteria associated with lean body mass.\nThe study found that both black and green tea changed the ratio of intestinal bacteria in the animals: The percentage of bacteria associated with obesity decreased, while bacteria associated with lean body mass increased.\nIn the study, four groups of mice received different diets -- two of which were supplemented with green tea or black tea extracts:\n\nAfter four weeks, the weights of the mice that were given green or black tea extracts dropped to the same levels as those of the mice that received the low-fat diet throughout the study.\nThe research is published in the European Journal of Nutrition.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders of the study are disclosed and there don\u2019t appear to be any obvious conflicts of interest.", "answer": 1}, {"article": "Hamilton says that \u201cduring this time, they\u2019re taught both approaches.\u201d But he adds that \u201csince 2009, of the 13 fellows he trained, 12 use the anterior procedure as their primary approach in their practices.\u201d\n\nHamilton says that \u201ca decade ago, very few residencies and fellowships taught the anterior approach.\nThe case of Daniel Ellsberg \u2014 who in 1971 released the Pentagon Papers, a secret study about U.S. involvement in Vietnam \u2014 is instructive.\nThe surgery is extensive: As its name suggests, it involves removing the joint \u2014 the damaged bone and cartilage \u2014 and replacing it with prosthetic parts made of metal, plastic or ceramics.\nBut with a relatively new procedure, surgeons enter from the front and only stretch the muscles aside, avoiding the cutting and minimizing pain and recovery time.\nAlso, I had a long list of restrictions of what I could and couldn\u2019t do so the hip wouldn\u2019t pop out.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a wide variety of sources. We wish that more of the \u201cold guard\u201d were represented, but we give it a pass here.", "answer": 1}, {"article": "But in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\nMay 23, 2011 -- Researchers in Europe say a fermented dairy product containing a specific bacterium known as a probiotic did not relieve constipation in children more than a dairy product without a probiotic.\nAbout half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A comment from one independent source was included in this story. \u00a0The story indicated that two of the researchers involved in the study reported on were employees of Danone Research. \u00a0Although not mentioned in the story, a third researcher who was extensively quoted in this piece is listed at her host institution, as conducting work funded by Danone and using products supplied by Danone in the work.", "answer": 1}, {"article": "The combination allowed many women with metastatic hormone-receptor-positive, HER2-negative cancer to delay the start of chemotherapy, which is the traditional treatment option in these patients once hormone drugs have stopped working.\nPalbociclib is a first-in-class drug - with a different mechanism of action to other approved drugs - which simultaneously blocks two proteins called CDK4 and CDK6 in cancer cells.\nIt provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease.\nThis trial is an exciting example of one of the most promising approaches to overcoming drug resistance, by combining drugs with different mechanisms of action to block off cancer's escape routes.\nSome 67 per cent of the 347 women in the palbociclib plus fulvestrant group showed clinical benefit - either a reduction in tumour size or control of disease for at least six months - compared with 40 per cent of the 174 women in the placebo plus fulvestrant group.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states that Pfizer funded the study. Pfizer produces palbociclib, one of the drugs studied in the trial.", "answer": 1}, {"article": "Henderson\u2019s team also found that the beneficial effect of HRT was stronger among women who had had a first-degree relative diagnosed with colon cancer.\nThe findings, reported in the American Journal of Epidemiology, support the theory that estrogen offers some protection against colon cancer.\nHowever, no one is recommending that women take HRT to ward off colon cancer.\nThe study, which followed nearly 57,000 California teachers, found that women who were using HRT at the outset were 36 percent less likely to develop colon cancer over the next decade than those who had never used HRT.\nThe findings are based on 56,864 menopausal women who took part in the California Teachers Study, a health study begun in 1995.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source cited was the lead author/researcher.\u00a0 We always wish stories would include an independent expert voice for additional perspective. ", "answer": 0}, {"article": "The results were published Wednesday in the journal JAMA Psychiatry.\nAn earlier study of 740 interns found that suicidal thoughts increased almost four-fold during the first three months of residency, said Dr. Constance Guille of the Medical University of South Carolina in Charleston.\nInterns who got the sessions were 40 percent less likely to have suicidal thoughts during that first year compared to those who received four weekly emails with information about depressions and where to seek help.\nShe said she became very depressed but had little time to seek help.\nThe research involved about 200 medical interns \u2014 residents in their first post-graduate year, which is often one of the most intense periods of doctor training.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides comments from a psychiatry resident not affiliated with the study who offers an important view from the inside.With that being said, we wish the story had included the views of an expert in the field, commenting specifically on the intervention that\u2019s the basis for the story.", "answer": 1}, {"article": "NEW YORK (Reuters) - Blood injections, especially of platelet-rich blood, into the affected area help relieve the pain associated with \u201ctennis elbow\u201d where other treatment methods have failed, according to a Greek study.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\nThe findings were published in The American Journal of Sports Medicine.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\nBoth groups experienced more improvement at 3 and 6 months after the injections, with no significant in pain scores between the treatments.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only relied on a single source.", "answer": 0}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert. The story should have quoted other experts who could have provided more balance.\u00a0 It could have turned to a spinal trauma expert from one of the many institutions that do not offer this form of treatment. ", "answer": 0}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\nIf you choose to try light therapy, here are a few tips from experts.\nSome say their patients don\u2019t have the patience to sit in front of a light for 30 to 45 minutes every morning.\n\u201cIt can help you from falling into a deep depression, but it won\u2019t help you climb out of one,\u201d he said.\nPatients generally sit in front of the light box, which can be as small as 9 by 11 inches and 5 inches deep, with the bright light emanating from the square surface, in the morning.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses independent sources, but strangely does not quote anyone who participated in the single research study cited from 2006.", "answer": 1}, {"article": "Companies like DexCom in San Diego now make small continuous glucose monitors whose sensors can be embedded in the skin.\n\u201cThis is something that companies have been striving to do for years, and as computer chip technology evolves, it gets closer,\u201d said Rick Wise, an analyst at Leerink Swann, a health care investment bank.\nIndeed, even if device makers are able to develop fully automated prototypes of combination systems, they are likely to face regulatory hurdles, analysts said, and would have to factor in product liability concerns.\n\u201cThe significance is in showing that the existing devices, which are available commercially, can be combined to create the first version of an artificial pancreas,\u201d said Dr. Roman Hovorka, the lead author of the study.\nBased on algorithms like the ones used in the Lancet study, the devices would continually monitor glucose levels, calibrate insulin dosages and then dispense insulin in real time \u2014 automating a delivery task performed by a nurse in the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes\u00a0from interviews with one of the study investigators and another researcher, and identifies both as having ties to diabetes products manufacturers. It also quotes an analyst at an investment firm. It would have been better had they\u00a0included one more source who didn\u2019t have commercial ties to specific products.\u00a0 ", "answer": 1}, {"article": "The guidelines state that from ages 40 to 74, screening will reduce the odds of dying from breast cancer, with women 40 to 49 benefiting the least and those 60 to 69 benefiting the most.\n\u201cWe believe the benefits increase with age.\n\u201cThe science supports mammography as an important tool in the fight against breast cancer,\u201d said Dr. Michael LeFevre, a former chairman of the task force and a professor of medicine at the University of Missouri.\nAmong those 40 to 49 who had regular screening, for every 1,000 women tested, 121.2 had a false positive.\nThe task force said it concluded \u201cwith moderate certainty\u201d that the benefit was moderate in women 50 to 74 and small in women 40 to 49.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did a good job of incorporating input from multiple independent sources.", "answer": 1}, {"article": "For more industry information, health research and recipe ideas, visit http://www.\n\"Our study results further support the growing body of research that tree nuts, such as walnuts, can reduce the risk of cardiovascular diseases,\" said Dr. Falk.\nAdditionally, results showed that tree nut consumption may be particularly important for lowering the risk of heart disease in individuals with type 2 diabetes.\nBeyond finding that tree nuts lower total cholesterol, triglycerides, LDL cholesterol and ApoB, researchers also found that consuming at least two servings (two ounces) per day of tree nuts, such as walnuts, has stronger effects on total cholesterol and LDL.\nThis study was supported in part by funds from The International Tree Nut Council Nutrition Research and Education Foundation.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states that the study is sponsored and funded by the California Walnut Commission with additional funding from the International Tree Nut Council Nutrition Research and Education Foundation.", "answer": 1}, {"article": "The researchers hope to develop an affordable device that people can use at home.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\n\u201cThat\u2019s very much tied to what part of the slow wave the stimulus is hitting on.\u201d\n\nThat doesn\u2019t mean there aren\u2019t benefits to other soothing background sounds.\nA small new study published in suggests that one easy way for older adults to get deeper sleep and stronger memories is to listen to a certain soothing sound called \u201cpink noise\u201d\u2014a mix of high and low frequencies that sounds more balanced and natural than its better-known cousin, \u201cwhite noise.\u201d\n\nIt may sound strange, but previous studies have found that playing so-called pink noise during sleep improves the memory of younger adults.\n\u201cWe wanted to see if it would work in older people, too,\u201d says senior author Dr. Phyllis Zee, professor of neurology at Northwestern University Feinberg School of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted in the article is a\u00a0study author. The article states that one of the study authors (it\u2019s not clear whether it\u2019s the one quoted or not) has co-founded a company to develop a commercial device.\nWe applaud the story for including this conflict of interest but we\u2019d like to see at least one source not involved in the study for an unbiased perspective.", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nSometimes a heart attack or stroke is the very first symptom.\nAbout 750,000 Americans have a heart attack every year.\nIt\u2019s inflammation, also.\nThey measure cholesterol, blood pressure and heart rate, they test the electrical signals that keep the heart beating and they may also run imaging tests to check for clogged arteries.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article appears to quote only those who conducted the study.", "answer": 0}, {"article": "In addition to trying colored-lens sunglasses, the article suggests other ways to mitigate photophobia including wearing a wide-brimmed hat when outdoors, adjusting digital screen and device settings to an appropriate hue and brightness or purchasing filters for screens.\n\"It is temporary but prevents further injury or pain.\"\nThe goal is to help the concussion patient feel better as the brain heals.\n\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nHowever, the researchers noted, they do not recommend wearing colored glasses while driving.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states, \u201cThere was no funding used for this study.\u201d", "answer": 1}, {"article": "\"By wearing the brace, I could get back to sports and was able to call my physician and say 'why didn't we try this first?'\"\nIn a new study, 49 people with knee OA aged 45 to 87 who wore a knee brace had less pain, stiffness, and disability after six months of use.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\nApril 13, 2010 -- Steve Peterson, 62, a home remodeler in Seattle, has rock-climbed in Tasmania, hiked in the high alpine regions of Washington, and trekked across the island of Manhattan -- all while sporting a knee brace due to painful knee osteoarthritis (OA), the wear-and-tear form of the disease that affects 27 million people.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included quotes from three clinicians and one patient \u2013 of which at least three appeared at the media briefing.\u00a0 There was no disclosure of any financial conflicts of interest among the three clinicians.\u00a0 Maybe there was none, but given the setting \u2013 a company-hosted media briefing \u2013 this issue should have been discussed. ", "answer": 0}, {"article": "\"This particular combination has been especially gratifying because not only does the SD-101 therapy drug induce tumor shrinkage at the actual site where it's injected, but it's working in conjunction with pembrolizumab to shrink tumors outside of the ones we're directly injecting.\"\n\"By understanding that, we can find more ways to make that therapy more active.\nThe other 13 people in the study had previously received a type of immunotherapy before the study.\nMerck & Co. provided pembrolizumab.\nThe study was funded by Dynavax Technologies Corp., which provided SD-101.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This information is included in the release.", "answer": 1}, {"article": "The protective effect for hip fractures disappeared.\nThe bad news is that there is no benefit of being less likely to develop heart disease, and any reduction in the risk of hip bone fractures evaporates with time, according to a report in the latest issue of the Journal of the American Medical Association.\nA new analysis of the landmark Women\u2019s Health Initiative, the federal study that discovered the health risks, indicates that women who stopped using estrogen after the dangers were uncovered are no longer at increased risk for strokes and blood clots about 10 years after they stopped.\nIn an editorial accompanying the study, Emily Jungheim and Graham Colditz of Washington University School of Medicine in St. Louis wrote that the findings indicate that while there \u201cmay still be a role for short-term use of unopposed estrogen for treating some women with menopausal symptoms ... this role may be vanishing as existing and emerging data continue to be better understood.\u201d\n\nRowan Chlebowski, one of the researchers who worked on the analysis, stressed that the study only looked at women who were taking estrogen alone.\nIn the new analysis, researchers analyzed data collected from 7,645 women who were in the part of the study examining the effects of taking estrogen alone an average of 10.7 years, after the study was halted because of the evidence the drugs were harming women.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019ll give the story the benefit of the doubt here, as it at least cited an accompanying editorial \u2013 although, as noted in the \u201cevidence\u201d criterion above, the NY\u00a0Times did a better job in eliciting clear quotes about context from its sources. ", "answer": 1}, {"article": "But Widra says women need to understand that success rates will never be 100 percent.\nThe whole process \u2014 a week of hormones, plus the procedure to collect the eggs \u2014 runs $12,000 to $14,000.\nWith the better survival rate from vitrification and other new freezing methods, more and more clinics are now offering what they call \"fertility preservation.\"\nAnd the uterus doesn't decline like eggs do; in some cases, it can actually be coaxed back into working order.\nNow, technology is dangling the possibility that women can stop that clock, at least for a while.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did a good job with asking a variety of potential patients for their opinions. It did not do quite so well in providing a diversity of medical experts.", "answer": 1}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a number of outside experts, including Riad Salem, chief of interventional oncology at Chicago\u2019s Northwestern Memorial Hospital;\u00a0Ken Thomson, a radiologist in Australia who studied the devices; and\u00a0\u00a0Tim Clark, director of interventional radiology at Penn Presbyterian Medical Center in Philadelphia. Importantly, the story also makes\u00a0the distinction\u00a0between the\u00a0claims the company\u00a0is making\u00a0and the claims being made by the clinics and\u00a0hospitals who have bought\u00a0the machines\u00a0(and are trying to recoup their investments.) It quotes the CEO of the machine\u00a0manufacturer saying,\u00a0\"We are not part of the whole PR machine. It\u2019s not something we are happy about.\"", "answer": 1}, {"article": "To learn more, visit njhealth.org.\nHowever, we know that eczema patients lack the beneficial bacteria needed to kill Staph aureus, harmful bacteria that can worsen eczema,\" said Donald Leung, MD, head of the Division of Pediatric Allergy & Immunology at National Jewish Health.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nThe next steps involve testing those different combinations, ensuring they're safe and conducting a longer trial to see if the benefits of bacterial cream can truly provide a permanent solution for eczema patients.\nIt may seem strange to fight bacteria with more bacteria, but it could lead to a long-term solution for eczema patients\n\nEczema is the most common skin disease worldwide.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources for this clinical trial are not mentioned. Potential conflicts of interest are also not addressed and this could be relevant since a quick check of the lead author on Dollars for Docs reveals multiple sources of industry funding in the past.", "answer": 0}, {"article": "He has changed his mind, and expects others will too: \u201cI think this report will make people more cautious.\u201d\nAs for vitamin D, some prominent doctors have said that most people need supplements or they will be at increased risk for a wide variety of illnesses, including heart disease, and autoimmune diseases.\nAt the same time, vitamin D sales have soared, growing faster than those of any supplement, according to The Nutrition Business Journal.\nIt is \u201ca very balanced set of recommendations,\u201d said Dr. Sundeep Khosla, a endocrinologist and the society\u2019s president.\nBut Andrew Shao, an executive vice president at the Council for Responsible Nutrition, a trade group, said the panel was being overly cautious, especially in its recommendations about vitamin D. He said there was no convincing evidence that people were being harmed by taking supplements, and he said higher levels of vitamin D, in particular, could be beneficial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The diversity of independent voices included in this story is a real strength. Although it solicits the obligatory comment from a supplement industry spokesman, it didn\u2019t go out of its way to find any of the more widely known vitamin D experts,\u00a0some\u00a0of whom have been issuing recommendations that are untenable based on current evidence. The enthusiasm of some of these researchers\u00a0might be\u00a0explained by\u00a0their significant career and financial\u00a0interests in promoting vitamin D.", "answer": 1}, {"article": "Specific means that the test is unlikely to be positive if cancer isn\u2019t really present.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\n\u201cThe men in the highest group have a risk of cancer on biopsy of about 70% and those in the lowest group have a risk of cancer of about 20%,\u201d says Tomlins.\n\u201cWhat we\u2019ve found is that your risk of having an aggressive cancer if you\u2019re in the high group is about 40%, and if you\u2019re in the low group, the risk of having an aggressive cancer is only about 7%,\u201d Tomlins says.\n\u201cThe real key is using this or any test to help drive decisions,\u201d says Jones, who was not involved in the research, \u201cIf it helps me to know who to biopsy or not biopsy, that\u2019s massively valuable information.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentioned that the study reported on was funded by the company making the test; and it also mentioned that several of the authors of the study had financial interests in the company.\nThe story included quotes from a study author, as well as Dr. Jones from the Cleveland Clinic, though there was no mention of whether Dr. Jones had any financial interest in the test reported on.", "answer": 1}, {"article": "For more information, visit http://www.\nThe study results showed that there was a higher number of callbacks among women ages 40-49 compared to women ages 50-59 (17% compared with 12.5%) and to women ages 60-69 (17% compared with 10.2%).\nWith educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2018 Annual Meeting, April 22-27, at the Marriott Wardman Park Hotel in Washington, DC.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nThe study to be presented by Abid Irshad of the Medical University of South Carolina examined the effectiveness of screening mammography between ages 40-49 in comparison to age groups 50-59 and 60-69.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release did not mention anything about funding sources or conflicts of interest for the study. Just because a radiology society put out a study that proposed using more radiology procedures doesn\u2019t mean that there was a conflict of interest; but without disclosures from the study, we can\u2019t be sure.", "answer": 0}, {"article": "The study included men and women.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\nWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d\n\nCorrection: The original version of this story misstated that all the participants were men.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While several of the study authors have ties to the pharmaceutical industry, it\u2019s not clear whether any of those companies are developing resveratrol-based drugs or supplements, and the study itself was funded by the NIH. Regardless, the story does lack input from any experts who weren\u2019t involved in the study, which is necessary to meet our standard here. The story would have been much stronger if it had included outside experts who could have placed the work in context and helped readers understand how this work fits into the broader scheme of Alzheimer\u2019s research and treatment.", "answer": 0}, {"article": "Learning skills for positive emotions result in less HIV in blood and less anti-depressant use\n\u2022 Positive emotions are possible even with stress of chronic health problems\n\u2022 Men using positive emotion skills learned to cope with their stress, while control group went on anti-depressants\n\nCHICAGO --- When individuals recently diagnosed with HIV were coached to practice skills to help them experience positive emotions, the result was less HIV in their blood and lower antidepressant use, reports a new Northwestern Medicine study.\nIn addition, the intervention group was significantly less likely to have repeating, intrusive thoughts about HIV.\nThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV.\nThe paper was published recently in the Journal of Consulting and Clinical Psychology.\nBased on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release noted the grants that supported the research. The study didn\u2019t note any financial conflicts of interest. ", "answer": 1}, {"article": "\"Our results demonstrate that [Opdivo] is more effective in treating patients with stage III and IV melanoma, cutting the risk of relapse by a third,\" lead researcher Dr. Jeffrey Weber, professor of medicine at NYU School of Medicine, said in a university news release.\nThe study is scheduled for presentation Monday in Madrid, Spain, at the annual meeting of the European Society for Medical Oncology.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\nThe study found that patients taking Opdivo had fewer severe side effects than those taking Yervoy, at 14 percent versus 45 percent.\nAnd at 18 months, the rate was 66 percent for Opdivo and 53 percent for Yervoy, the findings showed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story tells readers in the second paragraph that the study was funded by Bristol-Myers Squibb, which markets Opdivo. We like that the story places that information front and center. In addition, the story incorporates input from two independent sources.", "answer": 1}, {"article": "TUESDAY, Dec. 1, 2009 (HealthDay News) -- When used with ultrasound, elastography helps distinguish between cancerous and benign breast lesions, which reduces unnecessary biopsies, U.S. researchers have found.\n\"There's a lot of room to improve specificity with ultrasound, and elastography can help us do that,\" Dr. Stamatia V. Destounis, a diagnostic radiologist at Elizabeth Wende Breast Care in Rochester, N.Y., and the study's lead author, said in a news release from the Radiological Society of North America.\n\"The visualized portion of a skin lesion can be just the tip of the iceberg, and most dermatologists operate 'blindly' beyond what they can see on the surface,\" Siegel said.\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\nThey found that elastography correctly identified 98 percent of cancerous lesions and 82 percent of benign lesions, and they also determined that elastography was more accurate than ultrasound in gauging the size of the lesions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only experts who were involved in the study. Even worse, the two experts who are quoted are also quoted in the press release. The story should have also pointed out that the senior author is listed as an investigator for the company that produces the device used for the study.\u00a0 This is a major flaw of the story. Persepctives from independent sources could have tremendously improved the quality of the story.", "answer": 0}, {"article": "Why has it taken so long for hip arthroscopy to catch up to its shoulder and knee counterparts?\nThese tears are not detectable by X-ray, and though they usually can be seen by MRI, even those images can sometimes be inconclusive.\nThis means that a bone deformity causes the ball and socket to rub against each other in a way that pinches the labrum.\nWhile that is still done, restorative techniques have been introduced that allow for the preservation of the labrum instead of its removal.\nWhen minimal work is done, it can be four to six weeks; when FAI is corrected, it can be more like three to four months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n \nThe story includes interviews with two surgeons who perform a substantial number of hip arthroscopies. But the story should also include testimony from a trusted independent source who is not a proponent.", "answer": 0}, {"article": "Related: What Really Helps Knee Pain?\nThe three current recommended approaches for knee arthritis pain are physical therapy, non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen, or the opioid painkiller tramadol.\n\"It erased all of that.\u201d\n\nThe outpatient procedure typically takes about 40 minutes, is performed with local anesthesia and doesn\u2019t require an incision.\nThe treatment, recently approved by the Food and Drug Administration, is called \u201ccooled radio frequency ablation\u201d and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that don\u2019t make them a good candidate for surgery.\nFor some patients with structural problems of the knee, the procedure won't help, said pain specialist Dr. Edgar Ross, associate professor of anesthesia at Brigham and Women\u2019s Hospital.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has several independent sources. However, the story missed a potential conflict of interest. According to ProPublica\u2019s Dollars for Docs database, one of the story sources consults for at least two major medical device companies that make products similar to the \u201cCoolief\u201d system described in the story. That source also received small amounts of cash (for food and beverages) from Halyard Health, which makes the Coolief system.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A small U.S. study suggests daily hormone injections may boost mental agility in older people with and without mild cognitive problems.\nIt dwindles naturally with aging, which has been linked to declines in memory and executive function.\nThat is still unknown,\u201d said Petersen.\nIt\u2019s possible health problems could show up down the road, and the mental boost may be short-lived.\nIt\u2019s unclear how the test differences will translate into real life, said Baker.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A key independent expert was quoted.", "answer": 1}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All information in the story appears to come from company sources, though no one is quoted by name. [Other press coverage of the AstraZeneca statement fails to include additional comments from company spokesmen, suggesting the company did not provide more information to anyone.] \nUnnamed \"analysts\" are said to urge caution about the drug\u2019s market value until the results are published and information about side effects is known.\nBut the elephant absent from the room is the medical expert who could provide insight into Plavix\u2019s risk/benefit profile, how significant its risks are from a clinical perspective, and what value Brilinta would have if indeed it provides better outcomes and its effects are more quickly reversible. \nIt\u2019s significant to note that this medical information would be useful not just to consumers, but to Wall Street Journal readers who follow AstraZeneca\u2019s fortunes and who participate in the bloodsport of betting on drug blockbusters. \u00a0 ", "answer": 0}, {"article": "\"In addition, since this study was conducted at a single center and the primary [change in heart attack, stroke and death] was not statistically significant without adjustment for other factors, more studies and replication of these findings are needed,\" he said.\nOriginally from India, it is not associated with any particular religion or philosophy.\nFor those who meditated, there was a trend toward reduced smoking; however, this was not statistically significant.\nBoth groups increased exercise and drank less.\nIn addition, 20 people in the medication group had a heart attack or stroke or died, compared with 32 in the health education group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent cardiologist is extensively quoted, bringing an appropriate dose of skepticism to the\u00a0coverage.", "answer": 1}, {"article": "MONDAY, Aug. 15, 2011 (HealthDay News) -- A traditional Chinese herbal treatment may reduce fever from H1N1 (\"swine flu\") influenza just as well as the prescription medication Tamiflu, a new study suggests.\nThe results: Both M-Y and Tamiflu were effective at eliminating fever, whether administered on their own or in combination.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nAll three approaches helped to resolve fever sooner than no intervention whatsoever, the authors said, noting it appeared that fever dissipated fastest when M-Y and Tamiflu were given together.\nOne group was given 75 milligrams of Tamiflu twice a day in capsule form; a second group received 200 milliliters of M-Y four times a day in liquid form; a third group took the same dosages of Tamiflu and M-Y together; and a fourth group received no treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides commentary from one of the study authors and a representative of the dietary supplement industry. Neither of these sources could be called truly independent.\u00a0\u00a0A primary care physician or public health person could have provided\u00a0perspective about who is a candidate for treatment with antiviral drugs.", "answer": 0}, {"article": "Both are reasonable options.\u201d\nThe most common treatment for urinary incontinence is a daily dose of an anticholinergic medicine that alters the action of certain nerves.\nBotox injections are also used, often in cases where the medicine does not work.\nDry mouth was much more common in those who took the medicine; urinary infections and incomplete emptying of the bladder were more common in those given Botox.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no independent source quoted in this article. The only comment is from the lead author of the story.", "answer": 0}, {"article": "For more information, visit http://www.\n\"Our study highlights the fact that laparoscopic anti-reflux surgery is as effective as the open approach, and in 2017, with all its advantages, should be the standard of care,\" said senior study author Marco G. Patti, MD, FACS, a surgeon and Director of the Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill.\n\"Subsequently, the rate increased, but 15 percent of all anti-reflux operations were still being performed through an open approach in 2013.\nIn addition, indirect costs of the open approach, including an impaired ability to work, time off from work, and intangible costs of postoperative pain and healing, are difficult to measure but also favor the laparoscopic approach,\" said Dr. Patti.\n\"Patients with GERD have an incompetent lower esophageal sphincter, which allows gastric acid to go back up into the esophagus,\" said lead study author Francisco Schlottmann, MD, a surgeon at the Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not list any funding source for the research and the published study notes that authors had \u201cnothing to disclose.\u201d\u00a0 We\u2019ll rate this not applicable since this is an examination of existing data, and there may have been no additional outside funding.", "answer": 2}, {"article": "The new study, however, draws from the population.\n\"Nicotine replacement therapies ... do not show any long-term effect on quitting even when combined with counseling,\" says researcher Gregory Connolly, DMD, director of the Center for Global Tobacco Control and professor of public health at the Harvard School of Public Health.\nRelapse rates of the quitters were similar during the study period, whether they used the products alone or with counseling, or they did not use them.\nThe findings are at odds with clinical trials, Connolly says.\nThe results of the new study are published online in Tobacco Control.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We give the story a pass here because it includes one independent source with good perspective on both the study\u2019s strengths and drawbacks. Half of the people quoted in the story, though, either work for Glaxo or receive funding from Glaxo.", "answer": 1}, {"article": "Newswise \u2014 HOUSTON \u2015 For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused by treatment with immune checkpoint inhibitors (ICIs).\n\u201cWe have a limited amount of time to fix the problem so they can resume ICI treatment, but I feel that we\u2019ve made great progress in this area.\u201d\n\nThe researchers chose to investigate the potential for FMT as an alternative, compassionate-use therapy for patients suffering from refractory, or unresponsive, ICI-associated colitis.\nThe first patient\u2019s colitis resolved within two weeks following a single FMT treatment; the second patient experienced a partial recovery after the first treatment, followed by complete recovery after a second FMT.\nThe current data further suggests there is the potential for many molecular studies to better understand the role of the microbiome in driving ICI-colitis and immunotherapy response more broadly.\n\u201cIf the patient is a good responder to immunotherapy, that means you\u2019ve taken their effective treatment away,\u201d said Wang.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does identify funding sources, but it does not illuminate possible conflicts of interest.\u00a0 Admittedly, this would be hard to do given the large number of coauthors.\u00a0 But a section on \u201ccompeting interests\u201d in the Nature Medicine article that jump-started this release does indicate that some of the coauthors have a commercial interest in the success of microbiome treatment applications.", "answer": 0}, {"article": "[But] Kalydeco controls CF at the basic defect, so I'm OK with the other 'c' word, control, because I'm living it and I've never felt better in my life.\"\nThe only way to fix that would be gene therapy, where a healthy form of the gene would supplant the damaged one.\nThe announcement was supposed to be made in conjunction with three papers in the Sept. 8 issue of Science, but a reporter for Reuters got hold of the story early.\n\"We tested over 600,000 chemicals in cells with the defective protein that causes cystic fibrosis,\" says Van Goor.\n\"I was with my brother in Florida, and we were walking down the street, and I took a deep breath, and when I took a deep breath in and I let it out, I didn't cough,\" says Schaller.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter clearly did a lot of digging to craft this very well told piece, but the only two people ultimately quoted are Fred Van Goor at\u00a0Vertex Pharmaceuticals, which\u00a0developed the drug in question, Kalydeco, and\u00a0Emily Schaller, who was in a clinical trial for the drug and apparently saw a big benefit.\u00a0 No truly independent expert source was quoted.\n\u00a0", "answer": 0}, {"article": "TUESDAY, Feb. 28, 2012 (HealthDay News) -- Menstrual cramps are the bane of many women, but new research suggests that a form of vitamin D may one day be added to the meager list of pain relievers for the sometimes disabling condition.\nThe Italian study participants all had blood levels of vitamin D measuring in the lowest 25 percent of normal at the study's outset, although the researchers didn't report the womens' blood levels afterward.\nAfter two months, average pain scores dropped 41 percent for women assigned vitamin D treatment, while no difference in pain was reported in the placebo group.\nTo find out more about painful menstrual periods, head to the U.S. National Library of Medicine.\nThe vitamin is also known to have anti-inflammatory effects, Rabin added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interviews with other doctors not associated with the study and reported their viewpoints regarding the study findings.", "answer": 1}, {"article": "(Boston)--Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.\nWe believe that the protective effect of T on the CV system provides clinicians with the opportunity to utilize this approach for secondary prevention for hypogonadal men with a history of CV events,\" explained corresponding author Abdulmaged M. Traish, PhD, professor of biochemistry and urology at BUSM.\nIn addition, T is essential for overall health and well-being and for the prevention of osteoporosis.\nThe researchers followed a group of men for eight years who had been on TTh and compared them with another group of men who remained untreated for the same time period.\nIn the non-treated control group, there were 21 deaths, 19 of which were related to CV events.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "A study funder, Bayer Pharma, is not acknowledged although several coauthors are identified as receiving compensation from the company. Missing entirely from the press release is an acknowledgement that Bayer Pharma markets hormone replacement drugs to treat low levels of testosterone.", "answer": 0}, {"article": "Two studies published Tuesday lend support to controversial new cholesterol guidelines that could vastly increase the number of Americans advised to take cholesterol-lowering drugs called statins.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe editorial was written by Dr. Philip Greenland of Northwestern University, who is also a senior editor of JAMA, and Dr. Michael S. Lauer of the National Heart, Lung and Blood Institute.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story sought out and made good use of independent sources. It mentions that the guidelines were widely criticized and links to some printed criticisms made at the time. It quotes a variety of supportive and critical researchers regarding their opinions on the new research.", "answer": 1}, {"article": "A family of medicines known as tricyclic antidepressants were more effective at relieving global symptoms of IBS, the analysis found.\n\u201cThe decision should be made after considering all the pros and cons.\u201d\n\nLead author Dr. Alexander Ford of the University of Leeds in the U.K. didn\u2019t respond to requests for comment.\nAntidepressants may work better for certain types of IBS, and the study findings also suggest that the type of medication may matter, Kulak-Bejda said by email.\nFor the current analysis, researchers examined data from 53 trials that compared the effects of antidepressants or psychotherapy, either alone or in combination, versus placebo treatments or \u201cusual management\u201d in people with IBS.\nWhile some people improve with customized diets that avoid certain foods that trigger symptoms, this approach doesn\u2019t help everyone and some emerging research suggests that the condition may also be influenced by processes in the brain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from two third-party experts. The story does not speak to potential conflicts of interest, which is a shortcoming. We found no potential conflicts to report, but think it is worth making that clear in a story.", "answer": 1}, {"article": "The antidepressants can cause headache, nausea, dry mouth, dizziness and insomnia or sleepiness.\nFor the other antidepressants, Prozac and Celexa, and for the plant extracts, there was no statistically significant evidence that they worked for hot flashes.\nNow, other drugs have come into use for hot flashes, but not much is known about their effectiveness or long-term safety.\nThere were only two studies for Effexor, just one of which suggested it might help.\nThe report is based on a review of 43 studies of various nonhormonal drugs being used for hot flashes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study was not funded by any of the drug manufacturers with medications under study in the review. Principal investigators have no financial ties to drugs mentioned in the study, though the story does not mention this. ", "answer": 1}, {"article": "Oct. 18, 2010 -- Vitamin B12 may help protect the brain against Alzheimer's disease, according to new evidence that suggests the vitamin and an amino acid called homocysteine may both be involved in the development of Alzheimer\u2019s.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\n\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\nThe seven-year study followed 271 Finnish people ages 65 to 79 who did not have any symptoms of Alzheimer's disease at the start of the study.\n\u201cOur findings show the need for further research on the role of vitamin B12 as a marker for identifying people who are at increased risk of Alzheimer\u2019s disease,\u201d says researcher Babak Hooshmand, MD, MSc, with Karolinska Institutet in Stockholm, Sweden, in a news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "The approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\n\"These are patients who have been on drugs and may have had multiple angioplasties or CABG surgeries,\" AHA President Gordon Tomaselli, MD, tells WebMD.\nBlood was collected and processed to collect the stem cells, and then, using a catheter threaded into the heart, the researchers injected the CD34+ cells into areas of the muscle that had been identified as oxygen-deprived areas.\n\"Coronary artery disease involves not only the blockage of major arteries, but the death of small vessels, or capillaries, of the heart muscle,\" he says.\nThe new treatment came from the discovery about a decade ago that CD34+ stem cells stimulate the formation of new blood vessels, study researcher Douglas W. Losordo, MD, of Chicago's Northwestern University tells WebMD.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The president of the American Heart Association was quoted liberally throughout the story. It could be argued that since the work was published in an AHA\u00a0journal, he is not the most independent observer, but we\u2019ll give the story the benefit of the doubt on this. Independent researchers working in the field of stem cell experimentation might have been better choices.", "answer": 1}, {"article": "MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry.\nIt is also not clear how the device would work for patients with cranial implants, as metal interferes with the device's operating radio frequencies.\nHe predicts that the device has the potential to be used widely by emergency personnel but also to appear in other public spaces.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nAs the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the funding company, Cerebrotech Medical Systems, and notes that Cerebrotech \u201cpaid consultants to analyze the neuroimaging data independently.\u201d", "answer": 1}, {"article": "For those with early stage breast cancer, \"lumpectomy is just as effective if not more effective than mastectomy,\" said researcher Dr. Shelley Hwang, chief of breast surgery at Duke Cancer Institute in Durham, N.C.\n\n\"There are lots of women who think the more [treatment] they do, the better they will do,\" she said.\nThe study is scientifically sound in many ways, Kruper said.\nThis means their cancer depends on estrogen to grow.\nThe study was observational, Hwang stressed.\nIn this procedure, just the tumor and some healthy tissue are removed, sparing the rest of the breast.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did include the perspectives of two independent sources.", "answer": 1}, {"article": "Since amniocentesis carries a small risk of spontaneous miscarriage \u2014 Patsalis put it at around one or two percent \u2014 scientists have been looking for new less invasive ways to test for Down\u2019s and other potential genetic problems.\nIt involves taking a small amount of blood from the mother when she is between the 11th and 13th week of her pregnancy and detecting extra copies chromosome 21 in the fetus by analyzing the maternal blood.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nPatsalis\u2019 method takes advantage of differences in the DNA methylation patterns \u2014 which are important to control levels of genes \u2014 between mother and fetus.\n\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent perspective, which was sorely needed \u2013 especially regarding predictions of availability and impact on the field.", "answer": 0}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\nEven though the study\u2019s participants were not told whether they were assigned active or placebo treatment, one limitation of the experiment is that participants often stopped placebo treatments before the recommended 20-minute course of stimulation was done, the authors note in Neurology.\n\u201cWe worked on stimulation at a far away location, which makes the treatment more convenient and more discrete so people can use it even during working hours without anyone noticing,\u201d Yarnitsky added by email.\nIf the device works in larger trials and becomes widely available for migraine patients, it might offer an alternative for people who can\u2019t tolerate migraine drugs or an option patients could try in addition to medication when they don\u2019t get enough pain relief from drugs alone, Schoenen said.\n\u201cThe percentage of attacks for which TENS is sufficient as sole treatment and allows sustained pain relief remains to be determined,\u201d Schoenen cautioned.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included cautionary comments from a neurology researcher, which helps balance and contextualize the study\u2019s results.\u00a0The story also disclosed that the study was \u201ccompany-funded\u201d and that the study\u2019s lead author is \u201can advisory board member for Theranica, the company developing the device.\u201d", "answer": 1}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes perspective from an editorial that accompanied the studies in the journal, the Annals of Internal Medicine. And that\u2019s enough for a satisfactory grade. Reaching out to more sources, and actually talking to experts in this field, might have turned up additional insights worth sharing with readers.", "answer": 1}, {"article": "By six months, almost all had disappeared.\nAfter surgery to remove the bulk of the brain tumor, Badie and his colleagues directly injected the site with the modified immune cells (called chimeric antigen receptor T cells, or CAR T cells) six times, and the remaining part of this tumor stopped growing.\nIt\u2019s possible that the immune cells had destroyed most of the cancer cells expressing the original protein, so other cancer cells with other proteins began to proliferate and survive.\n\u201cIf we can do the same for other patients, that would be an amazing accomplishment that many decades of work and research on glioblastoma have never done,\u201d says Badie, whose own father passed away a decade ago from glioblastoma.\nBased on this man\u2019s case, his team is hoping to now inject not just the tumor site but also the ventricular space in the brain, since that may help control spread of the cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No outside sources were quoted, which is a vital aspect of any journalism regarding City of Hope Medical Center, which we\u2019ve called out for its \u201cmiracle mongering.\u201d An independent source\u2013such as we saw in our STAT review\u2013can be a vital way to ascertain\u00a0differing viewpoints on and help keep expectations in check.", "answer": 0}, {"article": "MONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests.\n\"There may be a population of MS patients that could be identified that might do well with transplant,\" he said.\nTo see how patients did over the long term after stem cell transplants, Saccardi and colleagues followed 281 patients from 13 countries who received stem cell transplants between 1995 and 2006.\nHe said, \"As neurologists battle with current therapies that are limited for progressive MS in younger patients, this study provides a possible new avenue for treatment.\"\n\"It's important to select patients in such a way that they actually get well with the transplant.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes input from one independent source (who highlighted the ethical concerns regarding treatment-related deaths for a nonfatal disease). He does not appear to have any relevant conflicts of interest.", "answer": 1}, {"article": "CHICAGO -- Acupuncture gets a thumbs-up for helping relieve pain from chronic headaches, backaches and arthritis in a review of more than two dozen studies -- the latest analysis of an often-studied therapy that has as many fans as critics.\nThe federal government's National Center for Complementary and Alternative Medicine paid for most of the study, along with a small grant from the Samueli Institute, a non-profit group that supports research on alternative healing.\n\"Perhaps a more productive strategy at this point would be to provide whatever benefits we can for our patients, while we continue to explore more carefully all mechanisms of healing,\" he wrote.\nThe analysis was more rigorous than most research based on pooling previous studies' results, because the authors obtained original data from each study.\nThe results \"provide the most robust evidence to date that acupuncture is a reasonable referral option,\" wrote the authors, who include researchers with Memorial Sloan-Kettering Cancer Center in New York and several universities in England and Germany.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an acupuncture \u201cskeptic\u201d and the author of an accompanying editorial. It mentions that the study was mainly funded by the federal government, with some additional funding from a non-profit with an interest in alternative medicine.", "answer": 1}, {"article": "Half ate 22 grams of freeze-dried blueberry powder (equivalent to a cup of blueberries) daily for eight weeks.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nThe study, in The Journal of the Academy of Nutrition and Dietetics, found that those who ate the blueberry preparation saw an average 5.1 percent decrease in systolic blood pressure (the top number) and a 6.3 percent decrease in diastolic pressure.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\n\u201cThere is something very special about the composition of blueberries that is responsible for their effect on blood pressure,\u201d she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not utilize any independent sources or expert analysis, something that might have clued readers into the study\u2019s limitations. In addition, there was no direct mention or description of any potential conflict of interest in the story. The study was partly funded by the\u00a0US Highbush Blueberry Council, and it stands to reason that they are very interested in increased blueberry sales as a result of greater health benefits.", "answer": 0}, {"article": "Even participants who had normal-range blood pressure, triglycerides or cholesterol levels before surgery saw improved measures.\nThe study authors had no part in which procedures the teens received.\nMost of the participants were female, most were white, and most received the gastric bypass.\nThose with the gastric band had an 8 percent drop in BMI.\nThe proportion of participants with two or three risk factors also dropped substantially.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes two sources who were not part of the study.", "answer": 1}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\n\"We don't want to send the message to people who have bone-on-bone, with big bone spurs and limited range of motion that they're all of a sudden going to get relief from injecting a little bit of cement into their bone,\" Hepinstall said.\nThe procedure involves a smaller incision than joint replacement surgery, so there's less risk of infection, and a quicker recovery time that means fewer of the side effects associated with being bedridden, Vasileff said.\n\"The claims that are being made are not evidence-based yet, although they are intellectually appealing,\" said Hepinstall.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two doctors and one patient served as sources of information for this news story. One of the doctors gave important commentary on the lack of evidence, which was good. However, according to Dollars for Docs, both doctors have received money from orthopedic device makers, some of which make products for this procedure. That should have been disclosed.", "answer": 0}, {"article": "But there are still hurdles to clear.\nThat medication, Topamax, has been dubbed dubbed \u201cSleepomax\u201d by doctors and patients because it\u2019s also a heavy sedative.\nWith the \u201cexquisite sensitivity\u201d of an antibody, however, scientists believe they can block CGRP without triggering dangerous side effects, Alder CEO Randy Schatzman said.\n\u201cI\u2019m very enthusiastic, as I think everyone in the field is, about having another treatment option for people with migraines,\u201d said Dr. Elizabeth Loder, a professor of neurology at Harvard Medical School and chief of the headache division in the department of neurology at Brigham and Women\u2019s Hospital.\n\u201cThere will certainly be hypercompetition,\u201d said William Ratner, Lilly\u2019s senior director of global headache marketing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes clear that four large drug companies are working to develop drugs, leading to an easy inference that the companies are funding the research. Among the story\u2019s sources, those working for the companies are so identified and others are characterized as unaffiliated with the companies. Nothing in the story broaches possible conflicts of interest.", "answer": 1}, {"article": "Surgery isn't the answer for all older lung cancer patients, according to Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society.\nSo they are referred for supportive care to control symptoms, rather than surgery to remove the cancer.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nAnd he found that a surprising number of these older patients did quite well.\nLike many patients his age, he didn't expect there would be any effective treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent source and we didn\u2019t note any potential conflicts of interest.", "answer": 1}, {"article": "\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\nHowever, more robust randomized, sham-controlled data are needed, with larger numbers of women, to evaluate long-term safety, benefits, and risks,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nIt further demonstrated that four or five laser therapies may be superior in lowering the intensity of GSM symptoms compared with three laser therapies in both short- and long-term follow-up.\nFounded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging.\nIn the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding for the study is not included.\nAlso relevant for readers, but not mentioned, is that two of the authors have financial ties to the company that produces the laser tested in this study.\u00a0Both authors have been expert witnesses for the laser company, suggesting a higher degree of approval of the therapy and potential for bias in the way the study is done.\nEqually relevant is that the National Menopause Society (NAMS)\u00a0 \u2014 which authored the news release \u2014 receives corporate support from about a dozen biotechnology companies, many that sell treatments targeted at GSM.\u00a0 Also, about three-fourths of the NAMS board have disclosed relationships with industry.", "answer": 0}, {"article": "SAN DIEGO -- Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective.\nHe says these qualities make this class of drug much easier to use than the traditional blood thinners.\n\"More recently, a number of new blood thinners called 'direct oral anticoagulants' have become available,\" says Dr. McBane.\nInjections are expensive at nearly $100 per day.\n\"These injections can be painful and cause considerable bruising at the injection site.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention any conflict of interests or funding sources. The website with the conference presentation abstract lists that the lead author received research funding from pharmaceutical company Pfizer.", "answer": 0}, {"article": "To find out more about the activities of EULAR, visit: http://www.\nFor further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress \n\nPress Office in Room 5B of Fiera Roma during EULAR 2015 or on: \n\nEmail: eularpressoffice@cohnwolfe.com \n\nOnsite tel: +44 (0) 7738 890 799 / +44 (0) 20 7331 5442 \n\nTwitter: @EULAR_Press \n\nYoutube: Eular Pressoffice\n\nThe European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.\n\"The optimal management of RA involves achieving the lowest possible disease activity - ideally remission, and then maintaining this level of control,\" said lead author, Dr. James Galloway, Department of Rheumatology, King's College Hospital NHS Foundation Trust, UK.\nOver the course of the congress there will be some 300 oral and just under 2,000 poster abstract presentations, more than 150 sessions, 400 lectures, 40 poster tours and 350 invited speakers.\nIn some cases however, patients maintained a clinical response after stopping the TNFi altogether.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No mention is made in the news release of who funded the study or whether there were any conflicts of interest. The study\u2019s lead author, Dr. James Galloway, said in an email to HealthNewsReview.org that the work was funded by Arthritis Research UK, a charity. The study itself says the authors declared no conflicts of interest.", "answer": 0}, {"article": "The study enrolled 119 participants.\nGUMC was one of 21 participating medical centers across the U.S.\n\nFurther studies, including analysis of frozen blood and cerebrospinal fluid taken from patients, are underway to test possible drug mechanisms.\nThe biggest risk factor for developing Alzheimer's is aging, and studies with animals found that most age-related diseases--including Alzheimer's--can be prevented or delayed by long-term caloric restriction (consuming two-thirds the normal caloric intake).\n\"A decrease in Abeta40 is seen as dementia worsens and Alzheimer's disease progresses; still, we can't conclude from this study that the effects of resveratrol treatment are beneficial,\" Turner explains.\nThe Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release discloses the funding source, which was the National Institute on Aging. The study\u2019s principal investigator R. Scott Turner, according to the disclosure statement attached to the original journal article, states he has received research support from Ceregene, Eli Lilly, Merck, Biogen Idec, Toyama, Elan/Transition Therapeutics and Pfizer, as well as the NIH and the DOD.\u00a0The news release doesn\u2019t list these disclosures, and says only that that Dr. Turner \u201creports no personal financial interests related to the study.\u201d\nWe\u2019d argue that it would have been better to list those disclosures in the news release, since they were deemed important enough to include the journal manuscript. But since we couldn\u2019t easily find any indication that these companies are developing resveratrol-based drugs \u2014 which would be a clear conflict of interest \u2014 we\u2019ll give the benefit of the doubt and rule this Satisfactory.", "answer": 1}, {"article": "WASHINGTON (Reuters) - A new, longer-lasting \u201cmorning-after\u201d pill to prevent unwanted pregnancy appears to work with no unexpected side effects, U.S. health regulatory staff said in documents released on Tuesday.\nWomen\u2019s health advocates have welcomed the potential for another contraceptive option, but some critics contend the drug is more akin to the abortion pill, sold by Danco Laboratories as Mifeprex and also known as RU-486 or mifepristone.\n\u201cData on pregnancy outcomes after EC (emergency contraceptive) failure with ulipristal were too limited to draw any definitive conclusions regarding the effect of ulipristal on an established pregnancy or fetal development,\u201d they wrote.\n\u201cThere is no doubt that ulipristal acts an abortifacient because the drug blocks progesterone receptors at three critical areas,\u201d an action that \u201cinterferes with the hormone action of progesterone to prepare the endometrium for implantation and to support the early pregnancy,\u201d the group wrote.\nIt was not clear what effect the drug had, if any, when a woman still became pregnant despite taking it, they added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes no independent sources outside of the FDA or the pharmaceutical company. Quoting independent sources to provide some perspective on what this might mean to women, would have greatly improved this story.", "answer": 0}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While readers can reasonably assume that the author of the materials will be paid a share of the sales proceeds, the release should have specifically disclosed whether the celebrity quoted in the release (Lou Pinella) was paid for his endorsement.", "answer": 0}, {"article": "MUSC operates a 700-bed medical center, which includes a nationally recognized children's hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center), Level I Trauma Center, Institute of Psychiatry, and the state's only transplant center.\nThe 149-bed hospital includes six community based outpatient clinics, a 20-bed nursing home, women's health, and the full range of inpatient and outpatient care, including medical and surgical intensive care.\nAs the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion, with an annual economic impact of more than $3.8 billion and annual research funding in excess of $250 million.\nAlthough these early, promising findings show that NAC reduced PTSD symptoms, craving, and depression, NAC should not be used as a monotherapy or substitute for evidence-based behavioral treatment, but instead be seen as an adjunct therapy that enhances it.\nThe SAIL rating ranks the Charleston VA in the top 10 percent of VA medical centers nationwide for quality of care and efficiency.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states the funding sources and it would be very unlikely that these researchers would have a financial interest in the product under study since it is off-patent and generically available without a prescription.", "answer": 1}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is the story\u2019s biggest shortcoming, as there are no independent sources, and it fails to note a number of significant financial conflicts of interest. The research funding appears to be spread among a number of foundations that wouldn\u2019t necessarily profit from PapSeek tests. However, the \u201ccompeting interests\u201d section details how 10 of the 37 authors stand to profit from the genes and tests used, including through patents, royalties, and equity \u2014 including five of the six corresponding authors.\nScientists having a financial stake in study is not uncommon, and doesn\u2019t necessarily weaken a study\u2019s results, but it should serve as a red flag to journalists to seek more outside expert opinions than normal. But the LA Times does not appear to have interviewed even one researcher not involved in the work, let alone without financial stakes in it. (Dr. Nickolas Papadopoulos, the only person quoted in the piece, is listed under several areas of stated competing interests in the study\u2019s notes.)\nThis information was easily found in the\u00a0news release.", "answer": 0}, {"article": "\"This is good news.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nIn a telephone interview, Gary Lyman of the American Society of Clinical Oncology said the findings will probably prompt the group to revise its recommendations for breast cancer patients accordingly.\nThe study provides \"strong evidence\" that many women can safely forgo lymph node removal, they wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article included quotes from an editorial accompanying the study and from an independent source at the American Society of Clinical Oncology.\u00a0 While the article did mention that the study was funded by the federal government, it would have been helpful for readers to know that it was funded by the National Cancer Institute.", "answer": 1}, {"article": "Elizabeth Williams, from the School of Biomedical Sciences at Queensland University of Technology, tells Newsweek the two studies \u201cdescribe tantalizing complementary and consistent results in Phase 1 trials in melanoma patients using vaccines.\"\nBut working out the unique mutations of each person\u2019s cancer, a time-consuming and complicated process, must first be identified before a vaccine can be developed for them.\nCancer vaccines that are personalized to the patient\u2014designed to help the immune system identify tumors as foreign bodies and destroy them\u2014have been considered as a potential treatment for a number of years.\n\"The vaccines are personalized for each individual\u2019s tumours by harnessing technologies that enable the comprehensive analysis of the molecular fingerprint of the tumour,\u201d she says.\nThey used a similar approach to Wu and her team to identify the mutations, then tested the vaccine on 13 people who were being treated for melanoma.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates insights from a few independent sources. This gives readers additional information about how the findings should be interpreted. However, no information is provided about potential conflicts of interest.", "answer": 1}, {"article": "Scientists from the University of Gothenburg\u2019s Sahlgrenska Academy have developed a portable pocket-sized vestibular, or balance, stimulation device in a bid to improve the lives of Parkinson\u2019s sufferers.\nBut this may not be restricted to Parkinson\u2019s disease, so there may be other conditions with poor balance where you could use electrical stimulation of the vestibular organs, the balance organs to improve balance and gait,\u201d he said.\nThe difference is that we use a particular current profile which you can stimulate the balance organs with without creating a balance disturbance.\nThe effectiveness of oral levodopa reduces as Parkinson\u2019s disease progresses in the patient and can lead to involuntary movements, or dyskinesia.\nThe researchers have also tested the method on ten Swedish Parkinson\u2019s patients, in both medicated and unmedicated states.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides useful comments from the primary study investigator, but that\u2019s not quite enough to earn a satisfactory rating here. At the least, we\u2019d expect\u00a0a comment from a clinician who cares for Parkinson\u2019s patients to provide some independent insight on this treatment.", "answer": 0}, {"article": "Even so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nThe review confirms the findings of another review in 2004, which also showed that probiotics had some effect against diarrhea.\n\"Surprising thing was it didn't really matter what type of probiotic was used or in which setting,\" Allen says.\nHowever, the impact of the probiotics varied greatly from study to study, researcher found.\nStephen Allen, a pediatrician at Swansea University in the United Kingdom who lead the review, tells Shots that probiotics were effective in almost all the studies, which had more than 8,000 participants total, his team evaluated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were cited in this story \u2013 only the lead author of the study.", "answer": 0}, {"article": "Antioxidants can also provide some protection but there has been controversy over the effectiveness of such food supplements, he said: \u201cPersonally, I think it is much better to eat lots of vegetables and fruit rather than taking any supplements.\u201d\n\nDr Richard Russell, a consultant respiratory physician in the NHS and medical advisor to the British Lung Foundation, who was not involved in the research, said the inhaler was both credible and promising: \u201cEctoine is a beautifully elegant molecule and it clearly works by helping water to stabilise, giving you a film of water in times of stress.\u201d\n\n\u201cThe work that has been published thus far, in credible, internationally recognised journals, show that this stuff has positive properties, protecting against triggered inflammation,\u201d he told the Guardian.\nA day later, it was announced that more ambitious plans for London from Mayor Sadiq Khan were overwhelmingly backed by the public.\nIt is expected to be available as an inexpensive, over-the-counter product.\nAn inhaler that protects the lungs against air pollution has been developed by scientists and could help the many millions of people affected by toxic air to avoid its worst effects.\nOutdoor air pollution is a global health crisis that kills over 3 million people a year and it has long been linked to lung and heart disease and strokes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Comments from one independent source are provided and the potential conflicts of interest of Dr. Klutman and Bilstein are in part duly noted.", "answer": 1}, {"article": "The results so far are very promising.\n\"We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren's disease,\" said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute.\n\"Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren's disease,\" said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.\nThe trial was run by the UKCRC accredited Oxford Clinical Trials Research Unit (OCTRU), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford.\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is a major weakness of the news release.\nAlthough sources of funding are included (Wellcome Trust, Department of Health, 180Therapeutics.com) in the release, it\u2019s not made clear that the two co-authors quoted have patents with 180Therapeutics related to this therapy.\nIn fact, the majority of the 17 authors listed on this study have financial ties to 180Therapeutics, a for-profit company focused solely on anti-TNF therapeutics (which the website mentions is a \u201c$30-billion annual drug market class\u201d).", "answer": 0}, {"article": "Women more likely to have serious mental health problems than men, study says\n\nNIH's mental health chief on why he's leaving for Google: Technology may hold key to better diagnosis\n\nMost Americans will get a wrong diagnosis at least once in their lives\nThe research, published Wednesday in JAMA Psychiatry, is significant because major depression is one of the most common mental health disorders in the United States and one of the leading causes of disability worldwide.\nThis study \"shows a new, proven-safe treatment of depression that is probably both more effective and less expensive than drug treatment or anything else,\" said Dan Kripke, a psychiatrist and professor emeritus at the University of California, San Diego, who has studied the topic but was not involved in the latest trial.\nThere's some evidence that depression, like jet lag, occurs when the biological clock is out of sync, and light helps to correct that, Lam said.\nBut now a study has found that light therapy also works in treating non-seasonal depression.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included a quote from an independent source other than study authors, so we\u2019ll award a Satisfactory. However, it would not have taken much to find someone who would have raised some questions about the study and offered a note of caution or two.", "answer": 1}, {"article": "But are they receiving it?\nA briefing posted on the site specifically states: \u201cCompared to tobacco products, electronic cigarettes are significantly safer.\u201d\n\nIn their paper, the researchers note that information on comparative risks is common for other products and activities, like over-the-counter medicines and even safety ratings of vehicles.\nThe day after the article was released, the Mayo Clinic removed the headline, replacing it with the still misleading statement that smokeless tobacco was \u201cnot a safe product.\u201d\n\n\u201cPeople can only make as good a decision as the information available to them allows,\u201d said Sweanor, an adjunct professor in the University of Ottawa\u2019s Faculty of Law who has spearheaded the development of world-leading tobacco control initiatives in Canada since the early 1980s.\nIn the case of providing information on differential health risks of nicotine products, \u201cThe evidence to date does not come close to establishing that there would be a loss to public health from making this information widely available from credible sources,\u201d Kozlowski says.\nTo illustrate their point, Kozlowski and Sweanor use the example that if one type of alcoholic beverage caused 3 in 5 regular users to die prematurely \u2014 as is the case with smoking traditional cigarettes \u2014 while another caused massively fewer deaths, consumers would want to know which product was the safer alternative.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "After years of reading stories about how Big Tobacco was behind many studies that questioned the danger posed by traditional cigarettes, a reader can be excused for thinking that, perhaps, the smokeless tobacco industry was funding the work published here. A look at the study shows that that was not the case, but few people reading the news release would get to that point. In cases where the index of suspicion is high, the news release would boost its own credibility if it was explicit that there were no conflicts of interest.", "answer": 0}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two surgeons who were not authors on the review in the Annals.", "answer": 1}, {"article": "Hair samples may help determine the risk of a child developing mental and other chronic illnesses later in their life, research led by the University of Melbourne has found.\n\u201cLooking at hair tells us new things.\u201d\n\nThe research is part of the ongoing Murdoch Childrens Research Institute\u2019s Childhood to Adolescence Study following a cohort of 1,200 children in and around Melbourne and was published in the journal, Psychoneuroendocrinology.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\nIt suggests hair cortisol levels may provide a marker of trauma exposure in children and identify those at risk of developing psychosocial and behavioural problems, and who may need medical and psychological support, leader of the study and a fellow in child and adolescent mental health at the University of Melbourne, Dr Julian Simmons, said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no conflicts of interest as determined from the authors\u2019 disclosures in the published study.\nBut the story quotes only the first author of the study in the article, and would have done well to get opinions of the work from at least one independent source. It\u2019s pretty unfortunate that\u00a0the story did not get an outside perspective, given the nature of the article and its claims.", "answer": 0}, {"article": "If you are interested in enrolling in a clinical trial, you can find one at clinicaltrials.gov.\nThe study shows the results of a six-month follow-up with patients in 2007, and researchers are presently working with data from the two-year follow-up.\nThe new results are a milestone in stem cell research, and for patients, said Jeffrey Karp, a researcher at Brigham and Women's Hospital in Boston, Massachusetts, who runs a stem cell biology lab at Harvard University.\n\"If we could increase the number of cells that could reach the heart, that would have significant advantages to this approach,\" Karp said.\nThe particular kind of cells used in this research are called mesenchymal stem cells, and come from adults, not embryos.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses two sources: One stem cell expert who is not involved with the research, and the lead author of the published paper.\u00a0\nWhile that\u2019s thin sourcing for a story of this length, it\u2019s sufficient to earn a satisfactory rating. ", "answer": 1}, {"article": "This gives them a tool.\u201d\n\nNow the looming questions are how to implement risk calculators in doctors\u2019 practices \u2014 and, Owens said, whether that benefits patients\u2019 health in the real world.\nDoctors generally add their own judgment to that decision as well.\nA researcher not involved in the work said it was a \u201cnice study\u201d that is a first step toward showing that tailored guidelines could have benefits.\nIt found that the tailored approach could prevent 43 percent more heart attacks and strokes than the simpler, general recommendations used now.\nDoctors, ideally, then adapt those guidelines to individual patients\u2019 situations.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The comments from the author of the editorial that accompanied the journal article were helpful.", "answer": 1}, {"article": "Harvard T.H.\n\"This work on the role of nutrition in early life and breast cancer incidence suggests one of the very few potentially modifiable risk factors for premenopausal breast cancer.\"\n\"From many other studies we know that breast tissue is particularly influenced by carcinogens and anticarcinogens during childhood and adolescence,\" said Walter Willett, Fredrick John Stare Professor of Epidemiology and Nutrition at Harvard Chan School and senior author of the study.\nThe researchers looked at a group of 90,534 women who participated in the Nurses' Health Study II, a large long-running investigation of factors that influence women's health.\n\"Previous studies of fiber intake and breast cancer have almost all been non-significant, and none of them examined diet during adolescence or early adulthood, a period when breast cancer risk factors appear to be particularly important,\" said Maryam Farvid, visiting scientist at Harvard Chan School and lead author of the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The National Institutes of Health and The Breast Cancer Research Foundation are named as funders. An existing financial arrangement between a lead researcher and the Japan Pharmaceutical Manufacturers Association is also disclosed in the release. It\u2019s not at all clear how this trade group was involved with the study or how its interests dovetail with a fiber-rich diet.", "answer": 1}, {"article": "Each carries problems.\n\u201cWith an average of one man dying every 45 minutes from prostate cancer in the UK, the need for a more reliable test that can identify dangerous forms of the disease earlier is greater than ever.\u201d\n\nIn the past few years, a number of celebrities have revealed that they had been diagnosed with prostate cancer and have joined campaigns to raise awareness of the disease, including Michael Parkinson, Ian McKellen and most recently Stephen Fry, the comedian and former rector of Dundee University, who this year described how he had surgery to deal with a prostate tumour.\n\u201cOur new method is far more accurate and also allows us to identify the difference between cancerous and benign tissue in the prostate without the need for invasive surgery.\u201d\n\nThe prostate is a small gland in the male reproductive system and is normally about the shape and size of a walnut.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\nPSA results can be unreliable; a DRE is not good at identifying which cancers are benign and which need treatment; MRI scans cannot always give a definitive answer; while a biopsy carries a risk of infection and is expensive.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the sources in the story were the same sources in the news release.\nThere is no mention of potential conflicts of interest among the researchers, even though this is a new technology which, if successful, could profit the researchers/inventors.", "answer": 0}, {"article": "For the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\nThe most common side effects in the CBD group were vomiting, fatigue and fever.\nFuture research will look at whether safety and tolerability might be improved and whether efficacy of CBD can be maintained at lower doses.\nIn the placebo group, there was a 13 percent reduction in seizures from about 15 monthly seizures to fourteen.\nGW Pharmaceuticals funded the clinical trial.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release mentions that the trial was funded by GW Pharmaceuticals, the manufacturer of Epidiolex.", "answer": 1}, {"article": "Plus, the American Society for Reproductive Medicine (ASRM) committee opinion on IVM states that implantation rates for IVM\u2014between 5.5 and 21.6 percent\u2014 are a more reliable indicator of IVM success and are lower than expected for women of the same age who use IVF.\nA study in the journal Facts, Views and Vision found that IVM achieved up to a 35 percent clinical pregnancy rate in young women, which is comparable to IVF.\nAnd for some women, those injections could even be downright dangerous.\nIVM has the potential to improve the chances for women to have babies without a long course of hormones.\nAlthough the treatment is used in conjunction with IVF, the initial process isn\u2019t the same.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does quote two sources who were apparently interviewed, although both are principals in reproductive medicine clinics selling their services.", "answer": 1}, {"article": "SUNDAY, Jan. 17, 2010 (HealthDay News) -- Giving a vaccine through a scratch on the skin (scarification) triggers a stronger immune response than injected vaccines, say U.S. researchers, who also found that scarification requires 100 times less vaccine to prompt an immune response.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\nAfter all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nScarification was first used nearly two centuries ago to give the first smallpox vaccinations.\nT-cells are located in lymph nodes and blood, as well as in peripheral tissues such as skin and lung.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources \u2013 only quotes from a lead investigator in a news release. ", "answer": 0}, {"article": "PROVIDENCE, R.I. [Brown University] -- New results from a clinical trial involving more than 900 military veterans at high risk for keratinocyte carcinoma skin cancer provides evidence that using the generic skin cream fluorouacil 5 percent for two to four weeks may reduce the risk of a squamous cell carcinoma (SCC) needing surgery by 75 percent within a year.\nThe finding that less than one month's use of fluorouacil 5% (5-FU) appeared to prevent cancer for up to a year is encouraging, said lead author Dr. Martin A. Weinstock, a professor of dermatology in the Warren Alpert Medical School of Brown University and chief of dermatology at the Providence Veterans Affairs Medical Center.\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged.\nBut in the new study, 5-FU appeared to provide prolonged protection after discontinuation and could be combined with sunscreen, Weinstock said.\nAfter the first year, 20 of the 464 veterans in the control group developed a squamous cell carcinoma that required surgery, but only five of the 468 veterans who got 5-FU did, a statistically significant 75 percent reduction in the risk, according to the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release points out that the study was funded by the Veterans Administration but omits the fact that several members of the research team received support from pharmaceutical firms. However, there\u2019s no indication that those connections played any role in the conclusions from the trial.", "answer": 0}, {"article": "D'Amico, chief of the Department of Plastic Surgery at Englewood Hospital and Medical Center in Englewood, N.J.\nThere are no guidelines requiring bariatric surgeons to warn their patients, although recently professional societies of plastic surgeons and bariatric surgeons have begun holding seminars to discuss the idea.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nTo manage pain and prevent long periods under anesthesia, most patients have the procedures done in stages over a series of weeks or months.\nMost insurers pay for bariatric surgery, but they often consider contouring to be cosmetic, rather than medically necessary, and thus not covered under their policies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although several plastic surgeons appear to have been quoted for this story, the perspective from a bariatric surgeon or a weight loss surgery program would have been more balanced rather than speculation about what patients are or are not told about excess skin.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A fresh look at the medical evidence shows women who eat more fiber are less likely to get breast cancer.\nFruits, vegetables, beans, and whole grains are all high in fiber.\nKnown benefits of a high-fiber diet include lower cholesterol and weight loss.\nAnd those in the top fifth of fiber intake were 11 percent less likely to do so than women in the bottom fifth.\nOf more than 710,000 women, 2.4 percent ended up with breast cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two expert independent perspectives were included.", "answer": 1}, {"article": "Anderson estimates Jardiance could boost Lilly\u2019s earnings per share by 8 percent on average across 2016 to 2020.\nThe vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.\nThat has not been the case with all things in diabetes,\u201d said David Marrero, president of health care and education at the American Diabetes Association.\nThe benefits were especially impressive because they added to protection that patients received from taking cholesterol fighters and other life-saving heart drugs, Zinman said.\nIt really is big news,\u201d said Dr. Bernard Zinman, director of the Diabetes Centre at Mount Sinai Hospital in Toronto, who led the three-year study of 7,000 people.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The initial version of this story includes only comments from Dr. Bernard Zinman, the lead investigator. The updated version of the story includes additional perspectives on the research, but neither version of the story makes it clear the the study was funded by\u00a0Boehringer Ingelheim and Eli Lilly, or that Dr Zinman and other co-authors disclosed financial relationships with Boehringer Ingelheim related to the study and outside of the study.", "answer": 0}]